PhytoMedical Technologies Inc (OTCBB:PYTO) - 500 Beiträge pro Seite

[js200]

PhytoMedical to Develop New Compound for Type-2 Diabetes

Monday , December 06, 2004 09:30 ET

VANCOUVER, British Columbia, Dec 6, 2004 (BUSINESS WIRE) --PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today announced its three-way Cooperative Research and Development Agreement (CRADA) with the USDA`s Agricultural Research Service (ARS) and Iowa State University.

The CRADA program, authorized under the Federal Technology Transfer Act of 1986, allows federal laboratories and businesses to form commercial partnerships that help move new technologies into the marketplace. PhytoMedical, through its wholly owned subsidiary, Polyphenol Technologies Corporation, has entered into the CRADA to, among other objectives, synthesize the active components found in cinnamon and characterize their beneficial effects in cell culture systems, animals and ultimately humans.

Over a ten year period, a team of ARS scientists led by Dr. Richard A. Anderson has isolated and characterized several polyphenolic compounds from cinnamon bark which increase sugar metabolism by a factor of 20 in test tube assays using fat cells. Impaired sugar and fat metabolism, present in millions around the world, may lead to type-2 diabetes and cardiovascular diseases.

"These new compounds increase insulin sensitivity by activating key enzymes that stimulate insulin receptors while inhibiting the enzymes that deactivate them," states Dr. Anderson, the lead USDA collaborating scientist.

Insulin is a hormone made by the pancreas to help the body use glucose (sugar) for energy. In people with type-2 diabetes, either the pancreas doesn`t make enough insulin or the body is unable to use it correctly. Without sufficient insulin, glucose accumulates in the blood and urine and the cells of the body are starved, a condition known as diabetes - the leading cause of end-stage renal disease, blindness and lower limb amputations.

Diabetes presently affects over 18.2 million Americans (American Diabetes Association) and is expected to rise to 30 million by 2030 (Centers for Disease Control). As one of the leading causes of death and illness worldwide, diabetes costs the American health care system over $132 billion each year.

Last year, Dr. Anderson and other research scientists published a study in Diabetes Care, a journal of the American Diabetes Association, on 60 people with type-2 diabetes who ingested small amounts of cinnamon daily. The study showed that as little as one gram a day of cinnamon - one-fourth of a teaspoon twice a day - can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

"The potential of this new discovery is incredible," comments Mr. Indy Panchi, President and CEO of PhytoMedical Technologies. "Lab tests in published studies, as well as a small, yet highly successful, human study show that cinnamon makes insulin more efficient."

Mr. Panchi continues, "Rather than have diabetics swallow raw cinnamon, our goal is to deliver a more potent synthetic compound that could be easily ingested as a pill or added to soft drinks or other liquids, with the end result being lower blood sugar levels through more efficient use of insulin."

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

The same compound, BDC-03, administered over a three month period to a healthy 45 year old male subject, resulted in a 5% reduction in body fat and a 15 pound gain in muscle mass, indicating that the additional weight had been preferentially shifted toward lean muscle - with no appreciable change in diet or exercise.

Additionally, the male subject did not experience any alterations in facial or body hair, exacerbation of acne or alterations in liver function tests, which are androgenic symptoms commonly experienced after treatment with anabolic steroids.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol is a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon - one-fourth of a teaspoon twice a day - can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit http://www.phytomedical.com/Alerts-Index.asp

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc.
Sarah H. Simpson, 800-611-3388
www.PhytoMedical.com


JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


12/06/2004 (09:30 ET) PhytoMedical to Develop New Compound for Type-2 Diabetes - Business Wire



12/02/2004 (16:55 ET) PYTO: Enters 3 Way Coop. Research & Develop. Agrmnt. - Knobias



12/02/2004 (16:49 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Knobias



12/02/2004 (11:05 ET) PYTO: Filed 8-K Regarding Research Scope Expansion (Nov-29 PR) - Knobias



12/02/2004 (11:04 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Knobias



11/30/2004 (11:55 ET) PhytoMedical expands R&D into obesity and diabetes - Datamonitor



11/29/2004 (10:11 ET) PYTO: New 52-Wk High @ $1.340 up 7.20% - Knobias



11/29/2004 (10:01 ET) PYTO: Volume Spike; 22% > 20-adsv, Stock +4.80% - Knobias



11/29/2004 (09:45 ET) PYTO: Expands Research Focus for Obesity and Diabetes - Knobias



11/29/2004 (09:30 ET) PhytoMedical Expands Research Scope To Include Obesity And Diabetes - Business Wire



11/26/2004 (10:10 ET) PYTO: Volume Spike; 18% > 20-adsv, Stock +1.82% - Knobias



11/26/2004 (09:53 ET) PYTO: New 52-Wk High @ $1.120 up 1.82% - Knobias



11/24/2004 (10:35 ET) PYTO: Volume Spike; 48% > 20-adsv, Stock +5.21% - Knobias



11/24/2004 (09:53 ET) PYTO: New 52-Wk High @ $0.980 up 2.08% - Knobias



11/23/2004 (10:50 ET) PYTO: Volume Spike; 15% > 20-adsv, Stock +3.85% - Knobias



11/23/2004 (10:36 ET) PYTO: New 52-Wk High @ $0.945 up 3.85% - Knobias



11/22/2004 (10:05 ET) PYTO: Volume Spike; 11% > 20-adsv, Stock EVEN - Knobias



11/22/2004 (09:57 ET) PYTO: New 52-Wk High @ $0.885 up 2.91% - Knobias



11/19/2004 (13:56 ET) PYTO: Volume Spike; 42% > 20-adsv, Stock +2.35% - Knobias



11/19/2004 (09:52 ET) PYTO: New 52-Wk High @ $0.870 up 2.35% - Knobias



11/18/2004 (10:35 ET) PYTO: Volume Spike; 37% > 20-adsv, Stock +10.53% - Knobias



11/18/2004 (09:52 ET) PYTO: New 52-Wk High @ $0.850 up 11.84% - Knobias



11/17/2004 (15:40 ET) PYTO: New 52-Wk High @ $0.820 up 22.39% - Knobias



11/17/2004 (10:50 ET) PYTO: Volume Spike; 13% > 20-adsv, Stock +11.94% - Knobias



11/15/2004 (16:57 ET) PYTO: Filed New Form 10QSB, Quarterly Report - Knobias


JS200

[js200]

PhytoMedical Expands Research Scope To Include Obesity And Diabetes

Monday , November 29, 2004 09:30 ET

VANCOUVER, British Columbia, Nov 29, 2004 (BUSINESS WIRE) --PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, announces its plans to expand its research and development efforts into two of the leading causes of mortality today - obesity and diabetes.

Obesity, according to the U.S. Surgeon General Richard Carmona, is the "fastest-growing cause of illness and death in the United States" and results in at least 300,000 deaths each year from obesity-related diseases, ranging from heart disease and diabetes to stroke and certain types of cancer, including breast, prostrate and colon (National Institutes of Health).

Treating obesity related health problems costs Americans $117 billion annually - an average of $420 per person. At present, statistics show that 65% of U.S. adults and 27% of children and teenagers are either overweight or obese, up from 47% and 12% respectively in 1980.

Today, more than 44 million adults are considered medically obese, an increase of 74% since 1991 according to the Centers for Disease Control and Prevention. So prevalent is the problem, that there`s a long waiting list for bariatric surgery, more commonly known as stomach stapling. Last year, over 80,000 people underwent the surgery, including Al Roker, NBC`s "Today" show weatherman and Sharon Osbourne of the "The Osbournes" on MTV.

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

"In addition to our first project targeting cachexia, a devastating muscle wasting disease which kills half of all late stage cancer patients and affects a quarter of all AIDS sufferers, we`re very excited to also pursue the research and development of novel, plant derived compounds for obesity and diabetes," states Mr. Indy Panchi, President and CEO of PhytoMedical Technologies.

"The answers to our most perplexing and complex medical challenges lie waiting amongst the 250,000 species of higher plants, where some 300 new drugs worth an estimated $150 billion still remain to be discovered," continues Mr. Panchi. "To date, less than 15% of these plants have been investigated for bioactive compounds, which are now contained in 25% of all prescription drugs, including twenty of the best selling drugs."

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (Symbol: PYTO), together with its wholly owned subsidiaries, is an early research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

The same compound, BDC-03, administered over a three month period to a healthy 45 year old male subject, resulted in a 5% reduction in body fat and a 15 pound gain in muscle mass, indicating that the additional weight had been preferentially shifted toward lean muscle - with no appreciable change in diet or exercise.

Additionally, the male subject did not experience any alterations in facial or body hair, exacerbation of acne or alterations in liver function tests, which are androgenic symptoms commonly experienced after treatment with anabolic steroids.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol is a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

For additional information, please visit www.phytomedical.com.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc.
Sarah H. Simpson, 800-611-3388
Web Site: www.PhytoMedical.com

JS200

[js200]

12/09/2004 (14:59 ET) PYTO: Filed 8-K Regarding New Compound Development (Dec-06 PR) - Knobias
12/09/2004 (14:58 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Knobias
12/06/2004 (09:30 ET) PhytoMedical to Develop New Compound for Type-2 Diabetes - Business Wire
12/02/2004 (16:55 ET) PYTO: Enters 3 Way Coop. Research & Develop. Agrmnt. - Knobias
12/02/2004 (16:49 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Knobias

[dottore]

Doppeltop - Finger weg
wenn überhaupt, dann unter 0,60 einsteigen

[js200]

12/21/2004 (10:37 ET) PYTO: Reported on by AllPennyStocks.com - Knobias
12/09/2004 (14:59 ET) PYTO: Filed 8-K Regarding New Compound Development (Dec-06 PR) - Knobias
12/09/2004 (14:58 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Knobias
12/06/2004 (09:30 ET) PhytoMedical to Develop New Compound for Type-2 Diabetes - Business Wire
12/02/2004 (16:55 ET) PYTO: Enters 3 Way Coop. Research & Develop. Agrmnt. - Knobias


JS200

[DerDackel]

Ach da schau her, die nächste Firma des Herrn Rayat wird hier also auch schon aufgegriffen. na dann bin ich mal gespannt, wann diverse Börsenbriefe die Aktie wieder für sich "entdecken"

Na ja aktuell läuft ja Hepalife noch "ganz gut" wenn man bei diesen wilden Ausschlägen überhaupt von irgendetwas handelsgeartetem sprechen kann), da kann mit der Entdeckung noch einen Augenblick gewartet werden.

[js200]

@DER DACKEL

Dear Reader,

For those of you working this week, here is a gift. Hepalife Technologies (HPLF) is committing fraud on the marketplace. With over a $300 million market cap, Hepalife has less than $100k in cash. Furthermore, the recidivist CEO Harmel Rayat is misrepresenting the company in both filings and in promotional materials.

Stocklemon believes Hepalife is a candiate for a HALT because of the background of the CEO that is not mentioned in the filings, and the misrepresentation of claims made by the company. Hepalife is nothing more than a stock promotion that is worth 0. More attention will be given to this story in the new year. Happy New Year and Cautious Investing To All.

Stocklemon.com

Die haben Gestern einen Dämpfer bekommen

JS200

[DerDackel]

Wer hat gestern einen Dämpfer bekommen ?

[js200]

Der Dackel

Gestern kam ein Stocklemonreport über HPLF

Steht ja drin, die scheinen schon mehrfach HPLF unter der Lupe gehabt zu haben

12.07.2004 Stocklemon Reports Law Enforcement Associates Part II
11.29.2004 Stocklemon Updates On Telkonet Inc.
11.08.2004 Stocklemon Reports On Telkonet Inc.
10.18.2004 Stocklemon reports on Law Enforcement Associates Corp.
10.15.2004 Stocklemon reports U.S. Canadian Minerals, Inc.
09.23.2004 Stocklemon Updates on YP.net
09.21.2004 Stocklemon Reports on Concorde America
09.14.2004 Stocklemon Updates on YP.net
09.09.2004 Stocklemon Updates on Whistler Investment Corp.
08.03.2004 Stocklemon Reports on Nitro Med.
06.25.2004 Stocklemon UPDATE ON US Medsys Corp.
05.26.2004 Stocklemon UPDATE ON YP.net.
05.24.2004 Stocklemon UPDATE ON YP.net.
05.20.2004 Stocklemon UPDATE ON YP.net.
04.15.2004 Stocklemon reports on Whistler Investment Corp.
04.13.2004 Stocklemon UPDATE ON YP.net.
03.12.2004 Stocklemon Reports on Whistler Investment Corp.
03.04.2004 Stocklemon UPDATE ON YP.net.
03.03.2004 Stocklemon UPDATE ON YP.net.
03.02.2004 Stocklemon UPDATE ON YP.net.
02.04.2004 Stocklemon UPDATE ON WORLD INFORMATION TECHNOLGY.
01.28.2004 Stocklemon Reports on Stocklemon Reports on Amerityre.
01.20.2004 Stocklemon Reports on Stocklemon Reports on Immtech International Part 3.
01.15.2004 Stocklemon Reports on WORLD INFORMATION TECHNOLOGIES.
01.12.2004 Stocklemon Responds to Allegations Made by YP.NET Inc.
01.08.2004 Stocklemon Reports On YP.net.
01.06.2004 Stocklemon Reports On Immtech International Part II.
12.12.2003 Stocklemon Reports On Verdisys.
11.20.2003 Stocklemon Reports on Immtech International.
10.27.2003 Stocklemon Reports on American Water Star Inc (AMWS) Part I.
10.21.2003 Stocklemon Reports on Interpharm.
10.10.2003 Stocklemon Reports on Hepalife and Patriot Gold.
09.22.2003 Stocklemon Reports on Interpharm Holdings Inc.
09.12.2003 Stocklemon Reports onTelkonet (PART III).
08.20.2003 Stocklemon Reports On Flight Safety Technology. Part II
08.12.2003 Stocklemon Reports On Flight Safety Technology. Part I
07.28.2003 Stocklemon Reports On Spear Jackson.
07.10.2003 Stocklemon Reports On Anscott Industries.
07.10.2003 Stocklemon Reports On Spear Jackson Part 1.
06.02.2003 Stocklemon Reports on Epixtar.
05.22.2003 Stocklemon Reports onTelkonet (PART II).
05.02.2003 Stocklemon Reports onTelkonet..
04.28.2003 Stocklemon Reports on American Oil and Gas.
03.26.2003 Stocklemon Reports on Storage Alliance (PART II).
03.24.2003 Stocklemon Reports on Storage Alliance (PART I).
03.14.2003 Stocklemon Reports on Epixtar.
02.25.2003 Stocklemon Reports on Macreport.net.
02.14.2003 Stocklemon Reports on Inernetstudios.
02.11.2003 Stocklemon Reports on RTIN Holdings
11.14.2002 Stocklemon Reports on Concentrax
10.23.2002 Stocklemon reports on Hemispherx Biopharma
10.14.2002 Stocklemon reports on Warp Technology Holdings
09.23.2002 Stocklemon reports on Lifestyle Innovations, Inc.
09.13.2002 Stocklemon reports on Matrix Energy Services
08.23.2002 Stocklemon reports on GeneMax.
08.02.2002 Stocklemon reports on Stratabase.
07.29.2002 Stocklemon Reports on Concentrax.
05.02.2002 Stocklemon Report on Advanced Technology Industries.
04.24.2002 Stocklemon.com Report on Duravest Inc.
03.26.2002 Stocklemon.com Report on E-Universe, Inc.
03.09.2002 StockLemon releases follow up on Energy Power Systems
01.30.2002 StockLemon releases follow up on Energy Power Systems
01.17.2002 Stocklemon releases report on Tel-One
12.28.2001 Stocklemon releases report on Humatech
12.12.2001 StockLemon releases follow up on E-City Software
12.05.2001 StockLemon releases report on E-City Software
11.19.2001 StockLemon releases report on Burrard Technologies
11.15.2001 StockLemon releases follow up on Energy Power Systems
11.13.2001 StockLemon releases report on Energy Power Systems
10.01.2001 StockLemon releases follow up report on Junum, Inc.
09.17.2001 StockLemon releases report on Netmaximizer.com
08.30.2001 StockLemon releases report on Xaibe, Inc.
08.21.2001 StockLemon releases report on Junum, Inc.
08.06.2001 StockLemon releases report on iJoin Systems

[DerDackel]

Steht ja drin, die scheinen schon mehrfach HPLF unter der Lupe gehabt zu haben

Ja das weiß ich. Die haben vor allem die Person Harmel Rayat auf dem Kieker und wenn man sich der "Erfolge" seiner vergangenen Firmen anschaut, bzw. wie diese aufgezogen worden und was sie jetzt noch wert sind - nun von Werten ist da nicht mehr viel übrig, zumindest nicht bei deren Aktionären.

Wenn ich mir die Kursentwicklung von HPLF anschaue, dann gleicht diese in den letzten Tagen eher einem Wild West Markt, denn einer Aktienentwicklung. Natürlich wird von einigen die gute Performance ins Feld geführt werden und für diejenigen, die dabei waren und zum richtigen Zeitpunkt ausgestiegen sind, freut es mich umso mehr, daß es in diesem Fall kein Geld gekostet hat. Die oftmals beschworene Langfristanlage kann hier sehr schnell zum Eurograb werden. Wie schnell der Absturz kommen kann sieht man ja jetzt und den vorherigen Anstieg dagegenzu setzen halte ich auch nicht für sonderlich aussagekräftig, denn hinter diesen ganzen Aktionen steckt teilweise System. Schon sehr oft wurden Firmen, bei denen die Aktienmehrheit von einigen wenigen kontrolliert wurde, nach oben getradet. So wurde neben einer guten Performance auch Interesse und eine gewisse Glaubwürdigkeit geschürt, irgendwann folgt der Absturz, in welchen viele Anleger hinein kaufen in der Annahme die Atien seien jetzt billig, da der Absturz "ohne Grund" erfolgt. Der Grund liegt meist darin, daß nun die Zeit für die Wenigen gekommen ist, das Volumen zum verkauf zu nutzen. Ob dies im Falle von HPLF auch so sein könnte, wird die Zukunft zeigen.

Nur die Historie der ein oder anderen Person zeigen eine deutlich positive Performance - allerdings nur im eigenen Geldbeutel. Die Zeche zahlen andere - die Aktieonäre, welche den Versprechungen und wundervollen Ausführungen geglaubt haben.

Im Sinne der Aktionäre würde ich mir wünschen, das es nun ausgerechnet in diesem Fall anders sein wird.

[js200]

@DER DACKEL

Wenn man Googelt --------> über die Person Harmel Rayat

dann wird einem schlecht

Als ich den Tread über PYTO aufmachte, ging es mir eher um die DIABETES

Da ich vieles zusammentrage über Wundheilung und Diabetes, war PYTO mir aufgefallen

Hier scheint mir mit der Person RAYAT immer das gleiche Spiel abzulaufen , er benutzt Richtlininien (Diabetes, Leberschaden) oder früher Internet, um grandios sich die Taschen zu füllen

Ich denke, genau wie du, die Hystorie der Person, könnte PYTO und HPLF zu Fall bringen, muss nicht sein, aber, Vorsicht ist besser.....................

Denn, von mehreren Dollars auf ----------> 0,0001 Dollar hat RAYAT schon mehrere Male geschafft

JS200

[Buddah]

die aktie wird von "frtalerts.com" als ("Ten Bagger" Biotech Stock...$1 to $10 medium term potential)gepusht...

[Buddah]

Time Magazine Reports On Cinnamon Molecule With ``Insulin-Like Properties`` For Type-2 Diabetes
Monday January 10, 10:09 am ET
PhytoMedical to synthesize newly discovered compounds from cinnamon for treatment of Type-2 diabetes; Studies show significantly lower blood levels of glucose, tryglycerides and cholesterol.


VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 10, 2005-- PhytoMedical Technologies, Inc. (OTCBB:PYTO - News), an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today reported that Time Magazine`s December 6th, 2004, cover story (The Year in Medicine from A to Z) referenced the benefits of a molecule found in cinnamon which has "insulin-like properties that may help people with Type-2 diabetes." A small study of Type-2 diabetes patients who ingested cinnamon had "significantly lower blood levels of glucose, triglycerides and cholesterol after taking cinnamon for 40 days."
Coincidently, on the same day of the Time Magazine cover story, PhytoMedical announced its intentions to synthesize the active components of several polyphenolic compounds from cinnamon bark that were isolated and characterized over a period of ten years by leading scientists. To review the Company`s December 6th, 2004 press release, please click here: http://www.phytomedical.com/IR/PressReleases/20041206-1.html…

Among other objectives, PhytoMedical plans to synthesize these polyphenolic compounds and characterize their beneficial effects in cell culture systems, animals and ultimately humans. These compounds, which increase insulin sensitivity by activating key enzymes that stimulate insulin receptors while inhibiting the enzymes that deactivate them, have increased sugar metabolism by a factor of 20 in test tube assays using fat cells. Impaired sugar and fat metabolism, present in millions around the world, may lead to Type-2 diabetes and cardiovascular diseases.

Insulin is a hormone made by the pancreas to help the body use glucose (sugar) for energy. In people with Type-2 diabetes, either the pancreas doesn`t make enough insulin or the body is unable to use it correctly. Without sufficient insulin, glucose accumulates in the blood and urine, and the cells of the body are starved, a condition known as diabetes - the leading cause of end-stage renal disease, blindness and lower limb amputations.

Diabetes presently affects over 18.2 million Americans (American Diabetes Association) and is expected to rise to 30 million by 2030 (Centers for Disease Control). As one of the leading causes of death and illness worldwide, diabetes costs the American health care system over $132 billion each year.

"In addition to published studies and a highly successful human study reported in Diabetes Care, a journal of the American Diabetes Association, it`s good to see that a leading and highly reputable magazine has picked up on the benefits of cinnamon and its incredible ability to make insulin more efficient," comments Mr. Indy Panchi, President and CEO of PhytoMedical Technologies.

Mr. Panchi continues, "Our job now is to develop a naturally derived synthetic end product that can be easily ingested as a pill or added to soft drinks or other liquids, with the end result being lower blood sugar levels through more efficient use of insulin without the risk or side effects of currently available pharmacological treatment options."

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO - News), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

The same compound, BDC-03, administered over a three month period to a healthy 45 year old male subject, resulted in a 5% reduction in body fat and a 15 pound gain in muscle mass, indicating that the additional weight had been preferentially shifted toward lean muscle - with no appreciable change in diet or exercise.

Additionally, the male subject did not experience any alterations in facial or body hair, exacerbation of acne or alterations in liver function tests, which are androgenic symptoms commonly experienced after treatment with anabolic steroids.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol is a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon - one-fourth of a teaspoon twice a day - can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit http://www.phytomedical.com/Alerts-Index.asp

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.



--------------------------------------------------------------------------------
Contact:
PhytoMedical Technologies, Inc.
Sarah H. Simpson, 800-611-3388
or
www.PhytoMedical.com

[js200]

01/24/2005 (10:35 ET) PYTO: Volume Spike; 13% > 20-adsv, Stock +13.04% - Knobias
01/24/2005 (09:15 ET) PhytoMedical Announces Bio-Processing Agreement with Drug-Discovery Contract Research Firm - Business Wire
01/19/2005 (15:16 ET) PYTO: Filed 8-K Regarding License Agreement (Aug-05 PR) - Knobias
01/19/2005 (15:13 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Edgar
01/18/2005 (06:00 ET) PYTO: mentioned in today`s Wall Street Journal - Knobias

[js200]

PhytoMedical Announces Bio-Processing Agreement with Drug-Discovery Contract Research Firm

Monday , January 24, 2005 09:15 ET

VANCOUVER, British Columbia, Jan 24, 2005 (BUSINESS WIRE) --PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today announced that Connecticut-based, Planta Analytica, LLC, will undertake the extraction, fractionation, and isolation of potentially active pharmacological elements in PhytoMedical`s BDC-03, a plant derived compound which has been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

Under the terms of the Bio-Processing Agreement, Dr. Jan A. Glinski -- a widely-published organic chemist and renowned specialist in natural products isolation and characterization -- will lead PhytoMedical`s fractionation-isolation research project at Planta Analytica`s laboratory facilities in Brookfield, Connecticut.

"We`re pleased to engage Dr. Glinski`s labs in this very important research," commented President of PhytoMedical Technologies, Mr. Indy S. Panchi.

"In early stage studies of growing animals, BDC-03 had the effect of decreasing the deposition of fat and, correspondingly, shifting overall weight increase toward lean muscle mass gain. This prospective ability of BDC-03 to preferentially shift overall weight gain in the form of lean muscle may well turn out to be a critically important therapeutic outcome for those suffering from cachexia, a deadly muscle wasting disease that afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients," explained Mr. Panchi. "In fact, half of all cancer related deaths are a result of cachexia and not the cancer itself.

"For the first time ever, BDC-03 research efforts will now focus on identifying the pharmacological components that may be responsible for this bioactivity. This is a very exciting time for our Company, and I`m especially grateful to recruit the invaluable scientific expertise of Dr. Glinski and his laboratory in the areas of organic and medicinal chemistry."

Dr. Jan A. Glinski holds a PhD degree in organic chemistry and has been in active scientific research for over 30 years. Among numerous career accomplishments, Dr. Glinski`s extensive experience with isolating active components from plant and microbial extracts is especially significant.

Notably, Dr. Jan Glinski is credited as the pioneer of protocols for high-throughput screening (HTS) of natural products extracts and elimination of false-positives, methods which remained in active scientific research practice for over a decade following his discovery.

In addition to postdoctoral research at University of Georgia, Athens, Dr. Glinski has undertaken research at the Georgia Institute of Technology, School of Chemistry, and tenured as Principal Scientist, Departments of Medicinal Chemistry, Analytical Sciences, Pharmaceutics and Clinical Research at Boehringer Ingelheim Pharmaceuticals, Inc., part of the world`s largest private pharmaceutical enterprise with over 30,000 employees and annual sales of more than $8.37 billion. Renowned for the first-ever successful use of microorganisms for large-scale product manufacturing, Boehringer Ingelheim first produced commercial phytochemicals as far back as 1895 and is a highly-regarded industry pioneer.

Today, at Planta Analytica`s laboratory Dr. Glinski`s ongoing research includes medicinal chemistry, extract purification, and successful implementation of novel separation technologies and development of innovative chromatographic and structural characterization methods.

"I`m delighted to be able to directly apply my most valuable research strengths to this project with PhytoMedical Technologies," announced Dr. Jan A. Glinski, Principal Scientist and Founder of Planta Analytica, LLC.

"In over three decades of scientific research, I have worked extensively with organic materials. With repeated success, I have identified the active ingredients in fractions, and have then further isolated the active molecules within these fractions for more advanced research," explained

Dr. Glinski. "In my opinion, this is a notable investigative drug-development research milestone for an early stage biopharmaceutical effort such as PhytoMedical`s BDC-03."

Dr. Jan Glinski is an active R&D consultant to the commercial biopharmaceutical industry, and a respected scientific collaborator to numerous regulatory and research agencies, including: The United States Pharmacopeia, a global leader in promoting medication safety and setting pharmacological standards; and a reviewer to the Journal of Natural Products, a top-ranked scientific journal in the field of medicinal chemistry, published jointly by the American Chemical Society and the American Society of Pharmacognosy.

Planta Analytica, LLC is accredited with `preferred vendor` status by the National Institutes of Health (NIH).

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

The same compound, BDC-03, administered over a three month period to a healthy 45 year old male subject, resulted in a 5% reduction in body fat and a 15 pound gain in muscle mass, indicating that the additional weight had been preferentially shifted toward lean muscle -- with no appreciable change in diet or exercise.

Additionally, the male subject did not experience any alterations in facial or body hair, exacerbation of acne or alterations in liver function tests, which are androgenic symptoms commonly experienced after treatment with anabolic steroids.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol is a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

For additional information, please visit www.PhytoMedical.com.

To receive future press releases via email, please visit
http://www.phytomedical.com/Alerts-Index.asp

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc.
Laura Rivers-Bowerman, 800-611-3388
Web Site: www.PhytoMedical.com

Copyright (C) 2005 Business Wire. All rights reserved.

[js200]

up

[js200]

PhytoMedical Announces Agreement with Celliance BioServices, Inc. to Conduct Animal Studies of BDC-03.
via COMTEX

February 22, 2005

VANCOUVER, British Columbia, Feb 22, 2005 (BUSINESS WIRE) --

PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today announced that the Company has signed an Agreement with Celliance BioServices, Inc. of Celliance(TM) Corporation -- a Serologicals Company -- to initiate further animal studies of BDC-03, a plant derived compound which has been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

Under the terms of the Agreement, Celliance BioServices will conduct PhytoMedical`s ongoing, early stage in vivo studies at its laboratories in Morgan Hill, California, a 30,000 square foot research facility known for its expertise in front-end, biopharmaceutical product development pipeline R&D.

"I`m very pleased that we`ve been able to enlist the expert scientific support of a well-respected leader in biopharmaceutical research and development services for these particular animal studies of BDC-03," commented President of PhytoMedical Technologies, Mr. Indy S. Panchi.

"These animal studies are especially important to us since they are designed to generate outcomes we believe will allow us to fully leverage PhytoMedical`s recently announced extraction-fractionation-isolation research initiative with PlantaAnalytica, LLC, a Connecticut-based drug discovery contract research firm with special expertise in organic chemistry and in isolating active components from microbial and plant extracts such as BDC-03," continued Mr. Panchi.

"I`m hopeful that collectively, our animal science research at Celliance BioServices and organic chemistry work at PlantaAnalytica, will help us better identify the pharmacological components that may be responsible for specific bioactivity observed in very early stage studies of growing animals."

In those studies, BDC-03 had the effect of decreasing the deposition of fat and, correspondingly, shifting overall weight increase toward lean muscle mass gain. This prospective ability of BDC-03 to preferentially shift overall weight gain in the form of lean muscle may well turn out to be a critically important therapeutic outcome for those suffering from cachexia, a deadly muscle wasting disease that afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia and not the cancer itself.

About Celliance BioServices, Inc.

Celliance BioServices is a division of Celliance(TM) Corporation (Serologicals Corporation (Nasdaq:SERO)). Celliance offers an expanding array of bioprocessing products and services including diagnostic products, contract research and manufacturing services, and cell culture media supplements. offering, EX-CYTE(R), the largest selling cell growth supplement, Probumin(TM), a proprietary line of bovine serum albumin and Incelligent(TM), the Company`s recombinant human insulin. It is also the world`s leading provider of monoclonal antibodies for the blood typing industry. Celliance is a Serologicals company based in Atlanta, GA.

Serologicals employs a total of more than 1,000 people worldwide in three Serologicals` companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.

For more information, please visit www.CellianceCorp.com, or www.Serologicals.com.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company specializing in the discovery, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit: http://www.PhytoMedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit: http://www.PhytoMedical.com/IR/PressReleases/20050222-1.html Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. Ms. Karley L. Smith, 800-611-3388 www.PhytoMedical.com

Copyright (C) 2005 Business Wire. All rights reserved.

[js200]

Competitive Advantages of PhytoMedical`s `Virtual` Research and Development Business Model.
via COMTEX

April 5, 2005

VANCOUVER, B.C., Apr 05, 2005 (BUSINESS WIRE) --

PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today commented on the competitive advantages of being a `virtual` company by using contract research organizations (CROs) and the benefits of its Cooperative Research and Development Agreement (CRADA), entered into with the USDA`s Agricultural Research Service (ARS) pursuant to the Federal Technology Transfer Act (FTTA).

"The concept of creating a `virtual` company by using and taking advantage of the resources offered by CROs is fast becoming what may be the most efficient and economic way for small cap companies such as ours to participate in the burgeoning biotechnology space, but also for advancing early stage research and the ultimate commercialization of the technologies," explains Mr. Indy Panchi, President and CEO of PhytoMedical Technologies.

One virtual drug development company led by a recognized authority in virtual drug development believes the virtual business model can reduce total drug development program costs by at least 25% and development times by up to 50%. "Such economies of time and money," states Mr. Panchi, "may permit a virtual company to maximize its access to resources, provide it with increased flexibility and efficiency, and enhance its competitive capabilities against larger and more traditional thinking pharmaceutical companies."

A virtual company business typically involves a small group of individuals in charge of strategic management, financial control and regulatory strategy. Functions involving, but not limited to, extraction, fractionation, isolation of active elements, animal studies, drug synthesis, toxicology, clinical and regulatory interactions and filings are generally outsourced to and carried out by either leading CROs with broad expertise or specialist CROs with specific capabilities.

Mr. Panchi continues, "One example of a successful virtual company is Angiosyn, which has operated on comparatively modest budget since its inception in 2003 by outsourcing its experimental treatment for blindness to outside contract companies. With just two employees, Angiosyn`s `virtual` business advanced sufficiently enough to be acquired recently by Pfizer for over $500 million." Mr. Panchi adds, "Of course, not all virtual companies will achieve that type of success."

"In essence, a virtual company is able to leverage available technologies and resources instead of investing shareholder capital on bricks and mortar," comments Mr. Panchi. "And nowhere is this more apparent than with our cooperative research and development agreement (CRADA) with the USDA`s Agricultural Research Service.

(PhytoMedical`s December 6, 2004 press release can be viewed at:

http://www.phytomedical.com/IR/PressReleases/20041206-1.html…

"In addition to advancing a technology that has already had over ten years of research and development expenditures by leading government scientists, our agreement also allows us access to fully-equipped modern research laboratory facilities -- which would otherwise be cost prohibitive for a small company such as ours." Mr. Panchi continues, "These tremendous savings in both time and infrastructure costs give PhytoMedical a unique advantage over many early stage biotechs who are forced to spend many years and many millions on research facilities, equipment and scientists to achieve the same kind of results."

The CRADA program, authorized under the Federal Technology Transfer Act of 1986, allows federal laboratories and businesses to form commercial partnerships that help move new technologies into the marketplace. PhytoMedical, through its wholly owned subsidiary, Polyphenol Technologies Corporation, has entered into the CRADA to, among other objectives, synthesize the active components found in cinnamon and characterize their beneficial effects in cell culture systems, animals and ultimately humans.

Over a ten year period, a team of Agricultural Research Service scientists led by Dr. Richard A. Anderson has isolated and characterized several polyphenolic compounds from cinnamon bark which increase sugar metabolism by a factor of 20 in test tube assays using fat cells. Impaired sugar and fat metabolism, present in millions around the world, may lead to type-2 diabetes and cardiovascular diseases.

Diabetes presently affects over 18.2 million Americans (American Diabetes Association) and is expected to rise to 30 million by 2030 (Centers for Disease Control). As one of the leading causes of death and illness worldwide, diabetes costs the American health care system over $132 billion each year.

Dr. Anderson and other research scientists published a study in Diabetes Care, a journal of the American Diabetes Association, on 60 people with type-2 diabetes who ingested small amounts of cinnamon daily. The study showed that as little as one gram a day of cinnamon - one-fourth of a teaspoon twice a day - can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Mr. Panchi further states, "Of course, our stockholders should be cognizant of the fact that although we believe that we have acquired rights to biomedical technologies demonstrating significant potential in preliminary studies, these results have not been evaluated by the Federal Food and Drug Administration; and that continued research and development is required in order to determine whether this technology may lead to products which can be used in the treatment of diabetes or whether the ultimate commercialization of these technologies is unwarranted."

PhytoMedical is not alone in seeking to develop promising biomedical technologies through CRADAs. Examples of some well known technologies developed through CRADAs include:

-- The National Cancer Institute`s CRADA with Bristol-Myers Squibb (NYSE:BMY), which resulted in the commercialization of Taxol(R), the first anti-cancer agent to surpass $500 million in US sales, and since FDA approval, has generated over $9 billion in revenues;

-- The CRADA between GlaxoSmithKline (NYSE:GSK) and the National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control and Prevention and the US Army, which resulted in the development and testing of Havrix(R), the world`s first Hepatitis A vaccine; and

-- Aviron`s CRADA with NIAID which resulted in the commercialization of FluMist(R), an influenza virus vaccine that has generated almost $80 million in revenues over the last two years. Aviron was acquired for $1.5 billion.

Mr. Panchi concludes, "The savings afforded to us by our virtual company business model and our CRADA agreement will allow PhytoMedical to spend our resources in other areas, including searching for and developing new and complimentary technologies, as well as enhancing shareholder value and building name brand recognition in the investment and biotechnology fields. This will allow us, among other things, improved access to new technologies, potential scientific collaborations; it will also increase the chances of attracting new members to our advisory board and Board of Directors. Additionally, by being better known in the biomedical technology space and in the investment community, our chances of obtaining research analyst coverage may improve and thereby, potentially making us more attractive to new investors as, if, and when we enter the capital markets for financing."

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit: http://www.PhytoMedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit:

http://www.PhytoMedical.com/IR/PressReleases/20050405-1.html

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. Ms. Karley L. Smith, Shareholder Communications 800-611-3388 www.PhytoMedical.com

Copyright Business Wire 2005

[js200]

otcstockexchange.com: Mid-Day Stock Alert -- OTCStockExchange.com SPRL, GTEL, DNAP, PYTO
via COMTEX

April 5, 2005

Rochester, NY, Apr 05, 2005 (M2 PRESSWIRE via COMTEX) --

OTCStockExchange.coms "Mid-Day Stock Watch Alert" this afternoon are Strat Petroleum, Ltd. (Pink Sheets: SPRL), GlobeTel Communications Corp. (OTCBB: GTEL), DNAPrint Genomics, Inc. (OTCBB: DNAP), PhytoMedical Technologies, Inc. (OTCBB: PYTO).

Sign-up for our FREE Stock Alerts at http://www.otcstockexchange.com !

Strat Petroleum, Ltd. (Pink Sheets: SPRL - http://finance.yahoo.com/q?s=SPRL.PK ) Strat Petroleum, Ltd. announced the initiation of the development of the Ementajevskoje oil field. With finalization of an agreement to receive funding and develop the first well, the company has begun a feasibility study of the site which should be completed sometime in April.

The Ementajevskoje oil site, the license to which is currently owned by the Industrial Scientific Centre, has proven reserves of over 11.25 million barrels of crude oil, and probable reserves of over 26.0 million barrels. The company has an agreement with the Industrial Scientific Centre to establish a 50/50 joint venture, and an 80% net profit interest to develop the field.

Upon completion of the feasibility study, the company will order the drilling rigs out to the site, and expects drilling to commence in early May. Production is expected to begin in late June.

"We are very excited to see our plans progress," Sam Hyams, President and Chief Executive Officer of Strat Petroleum Ltd was quoted as saying. "We had hoped to begin developing and drilling within 60 to 90 days of the announced agreement on February 16th of this year, and we feel confident with that timeline."

In other news, the Company announced its continued due diligence progress on analyzing and verifying geological and legal documentation presented to the company on other fields, and expects to release further updates in the very near future.

Strat Petroleum, Ltd.`s strategy is to enhance shareholder value through the acquisition of oil & gas properties with proven reserves or producing/capped wells. Should you wish any additional information on our projects or management team, please visit our website at http://www.stratpetroleum.com or contact our Investor Relations office. Due to the volume of interest we will make every effort to respond as promptly as possible.

GlobeTel Communications Corp. (OTCBB: GTEL - http://finance.yahoo.com/q?s=GTEL.OB ) GlobeTel Communications Corp. today announced that its wholly-owned subsidiary, Sanswire Networks, LLC (Sanswire), will be unveiling its prototype high altitude airship, Sanswire One, in California on April 12, 2005 as previously announced.

The unveiling will be held between 2 p.m. and 4 p.m. Interested shareholders and other parties should arrive at the San Bernardino Hilton (909-889-0133) before 1:30 p.m., where they will be shuttled by bus to the Sanswire construction facility, returning at approximately 4.00 p.m.

People who wish to attend should register by sending a confirmatory email to [e-mail]. For more information interested parties should contact Leigh Coleman at [e-mail].

According to Timothy M. Huff, CEO of GTEL, "Sanswire One has undergone a significant construction program since February 22, when we held our Technology Summit in San Bernardino. Sanswire One marks the beginning of an exciting phase in the development of the Company`s high altitude platform program. At the unveiling, we will answer questions concerning the airship construction and performance. We will also give an updated timeline to the future events of Sanswire One."

Soon after the unveiling, Sanswire One will be moved to Edwards Air Force Base where the actual launch will take place. Mr. Huff stated, "Our plans are to launch at Edwards AFB, under the direction of NASA and the Air Force. Each agency will have to approve the flight plan before the launch date. By launching it from Edwards, we will be using non-FAA regulated air space which should expedite the flight safety approval process. Until the launch date, we will be doing ground base test and begin the process on the construction of Sanswire 2, the 400-foot long commercial airship. Sanswire 2 will be constructed in our new facilities near Edwards AFB."

A public announcement will be made on April 13 to give an update for those who couldn`t attend the unveiling which will include pictures of Sanswire One.

DNAPrint Genomics, Inc. (OTCBB: DNAP - http://finance.yahoo.com/q?s=DNAP.OB ) DNAPrint Genomics, Inc. today announced that it has acquired an exclusive worldwide license from Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) to develop a new, more potent and longer-acting form of the anemia drug Erythropoietin (EPO).

The licensing agreement is part of an overarching strategy to utilize recent genomics and chemistry advances made by researchers at DNAPrint to develop next-generation drugs that maximize efficacy and minimize side effects by tailoring medication for specific individuals and well-defined population sectors.

The royalty bearing licensing agreement creates an opportunity for DNAPrint genomics to develop and market an improved "Super"- EPO. EPO is currently commercialized by several pharmaceutical companies for a worldwide market that exceeds $10 billion, and the EPO market is growing at an average annual rate of 21%. Leading participants in the existing monomer EPO market include Amgen, Johnson & Johnson and Roche.

EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the marketed forms are manufactured by recombinant DNA technology and are used to treat anemia or low blood cell count that results from a variety of illnesses and conditions. PT-401, the improved version of EPO licensed by DNAPrint, is an Erythropoietin dimer, or a double form of the natural protein.

"With the first pharmaceutical in our nascent drug pipeline, our Company is evolving into a genomics-based pharmaceutical company that develops innovative `theranostic` products, which blend genomics-based tests with drugs as products to target segments of the patient population for enhanced efficacy and reduced side effects," stated DNAPrint genomics Chief Executive Officer Richard Gabriel. "Everything we have done as a company up until this point -- aggressively introducing new tests, forging new markets, expanding the envelope of genomics expectations in the fields of forensics, consumer genomics and pharmacogenomics -- has made today`s announcement possible."

"DNAPrint genomics has taken a major step forward in establishing a drug pipeline that has the potential to provide the Company a significant opportunity for growth," stated Tony Frudakis, Ph.D., Founder and Chief Scientific Officer. "We are pleased that a prestigious organization such as Beth Israel Deaconess is embracing our innovative technology in the development of our first drug candidate."

"Starting immediately, we intend to devote a very significant proportion of our resources to fund and execute the PT-401 development program. EPO exhibits an element of variable response that DNAPrint management believes Company technology can help address. PT-401 will be coupled with a genetic test for predicting response and individualizing dosage, thereby providing personalized treatment," said Hector J. Gomez, MD, Ph.D., DNAPrint`s Chairman and Chief Medical Officer. "We believe we have made a wise choice in selecting PT-401 to apply our genomics expertise -- expertise which is not restricted to xenobiotic metabolism genetics but inclusive of far more complex gene-drug interactions."

"Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin," stated BIDMC`s Dr. Arthur J. Sytkowski, who holds patents related to the new "Super"-EPO. "We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug."

The human gene that produces EPO was cloned in 1985, and, in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN , a drug that many credit for the rise of Amgen in the 1990s as one of the world`s most successful biotechnology companies ever.

Patients undergoing certain therapies or with certain conditions are often rendered anemic, meaning their red blood cell count drops dramatically. Without adequate amounts of erythropoietin in the blood, red blood cells are not regenerated efficiently, and there are too few red blood cells to deliver oxygen sufficiently throughout the body.

Erythropoietin has been approved by the U.S. Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Anemia leaves patients tired, often impairing their ability to work or perform even routine tasks and over the last decade, EPO has proven to improve quality of life and overall fitness of those patients.

In 1995, Dr. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess, was awarded the first in a string of eight patents covering methods of producing and using recombinant protein multimers with increased biological activity. In these patents, which are subject of the exclusive DNAPrint license announced today, Dr. Sytkowski described a new dimer (double) form of EPO -- "Super"-EPO, that elicited a heartier, more predictable hematocrit (red blood cell count) response, constituting a significant improvement over existing EPO technology.

PhytoMedical Technologies, Inc. (OTCBB: PYTO - http://finance.yahoo.com/q?s=PYTO.OB ) PhytoMedical Technologies, Inc. an early stage research based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today commented on the competitive advantages of being a `virtual` company by using contract research organizations (CROs) and the benefits of its Cooperative Research and Development Agreement (CRADA), entered into with the USDA`s Agricultural Research Service (ARS) pursuant to the Federal Technology Transfer Act (FTTA).

"The concept of creating a `virtual` company by using and taking advantage of the resources offered by CROs is fast becoming what may be the most efficient and economic way for small cap companies such as ours to participate in the burgeoning biotechnology space, but also for advancing early stage research and the ultimate commercialization of the technologies," explains Mr. Indy Panchi, President and CEO of PhytoMedical Technologies.

One virtual drug development company led by a recognized authority in virtual drug development believes the virtual business model can reduce total drug development program costs by at least 25% and development times by up to 50%. "Such economies of time and money," states Mr. Panchi, "may permit a virtual company to maximize its access to resources, provide it with increased flexibility and efficiency, and enhance its competitive capabilities against larger and more traditional thinking pharmaceutical companies."

A virtual company business typically involves a small group of individuals in charge of strategic management, financial control and regulatory strategy. Functions involving, but not limited to, extraction, fractionation, isolation of active elements, animal studies, drug synthesis, toxicology, clinical and regulatory interactions and filings are generally outsourced to and carried out by either leading CROs with broad expertise or specialist CROs with specific capabilities.

Mr. Panchi continues, "One example of a successful virtual company is Angiosyn, which has operated on comparatively modest budget since its inception in 2003 by outsourcing its experimental treatment for blindness to outside contract companies. With just two employees, Angiosyn`s `virtual` business advanced sufficiently enough to be acquired recently by Pfizer for over $500 million." Mr. Panchi adds, "Of course, not all virtual companies will achieve that type of success."

"In essence, a virtual company is able to leverage available technologies and resources instead of investing shareholder capital on bricks and mortar," comments Mr. Panchi. "And nowhere is this more apparent than with our cooperative research and development agreement (CRADA) with the USDA`s Agricultural Research Service.

About OTCStockExchange.com

OTCStockExchange.com (OTCS) is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. OTCS is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. OTCS`s goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. OTCS provides all investors with the latest news, press releases, investment opinions, and research reports for all the companies highlighted on the site. OTCS offers a free financial newsletter. To subscribe or get more information, visit our home page located at http://www.otcstockexchange.com.

OTCStockExchange.com (OTCS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by OTCS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.otcstockexchange.com or mentioned herein. OTCS has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion.

OTCS has been compensated by third party shareholders or with cash from the company on behalf of SPRL. OTCS has been compensated 50,000 shares on behalf of SPRL for dissemination of this opinion and other professional services.

OTCS`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. OTCS will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCS undertakes no obligation to update such statements.

CONTACT: e-mail: [e-mail] WWW: http://www.otcstockexchange.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD

[js200]

04/05/2005 (13:04 ET) otcstockexchange.com: Mid-Day Stock Alert -- OTCStockExchange.com SPRL, GTEL, DNAP, PYTO - M2 Communications
04/05/2005 (11:20 ET) PYTO: Volume Spike; 315% > 20-adsv, Stock +16.00% - Knobias
04/05/2005 (09:15 ET) Competitive Advantages of PhytoMedical`s `Virtual` Research and Development Business Model. - Business Wire
03/31/2005 (16:09 ET) PYTO: Filed New Form 10KSB, Annual Report - Edgar
03/08/2005 (12:39 ET) PYTO: Draws Down $750K from Loan Commitment - Knobias

[js200]

Last Trade: 1.180 Change: 0.180 (+18.000%)
Previous Close: 1.000 Volume: 1,444,000
Bid: 1.160 Ask: 1.180
Today`s Open: 1.010 # of Trades: 287

[js200]

PhytoMedical Announces Plans to Bolster Ongoing Scientific Initiatives with Expansion of Research Team
via COMTEX

April 19, 2005

VANCOUVER, British Columbia, Apr 19, 2005 (BUSINESS WIRE) --

PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early-stage research-based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant-derived pharmaceutical and nutraceutical compounds, today unveiled plans to enhance its ongoing research efforts through accelerated expansion of its scientific research team.

"We believe that the time is right for us to fully leverage the Company`s resources and aggressively advance our primary research through the addition of key scientific research staff," announced Mr. Indy Panchi, President and CEO of PhytoMedical Technologies.

"I`m particularly keen on seeing our early-stage scientific efforts move us towards synthesizing compounds that improve the action of insulin, and can be used to control blood sugars and fats," explained Mr. Panchi. "Our primary objective is to synthesize the active components found in cinnamon and characterize their beneficial health effects in cell culture systems, animals and ultimately humans."

Insulin potentiating components, which have been found in cinnamon and have already been isolated and characterized, may be very important in the control of glucose intolerance and diabetes. In fact, in test tube assays using fat cells, sugar metabolism has increased by a factor of 20. Impaired sugar and fat metabolism, present in millions around the world, may lead to type-2 diabetes and cardiovascular diseases.

According to current estimates, diabetes now affects over 18.2 million Americans (American Diabetes Association) and is expected to rise to 30 million by 2030 (Centers for Disease Control). As one of the leading causes of death and illness worldwide, diabetes costs the American health care system over $132 billion each year.

Taking aim at diabetes, PhytoMedical earlier announced its research initiative to synthesize the active components of several polyphenolic compounds from cinnamon bark that have been isolated and characterized over a period of ten years by leading scientists.

(To review the Company`s December 6th, 2004, press release, please click here: http://www.phytomedical.com/IR/PressReleases/20041206-1.html…

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO), together with its wholly owned subsidiaries, is an early-stage research-based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant-derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best-selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body

Fat Percentage

Named BDC-03, PhytoMedical`s first plant-derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer-related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower-limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes, including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com.

To receive future press releases via email, please visit: http://www.PhytoMedical.com/Alerts-Index.asp.

To view the full HTML text of this release, please visit: http://www.PhytoMedical.com/IR/PressReleases/20050419-1.html…

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including, but not limited to, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc., Vancouver Karley L. Smith, 800-611-3388 www.PhytoMedical.com

Copyright Business Wire 2005

[js200]

PhytoMedical to Obtain Up to $10,000,000 in Equity Financing
via COMTEX

July 11, 2005

VANCOUVER, British Columbia, Jul 11, 2005 (BUSINESS WIRE) --

PhytoMedical Technologies, Inc. (OTCBB:PYTO), an early stage research based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today announced that it has entered into an agreement to raise up to $10 million in equity financing from Fusion Capital Fund II, LLC, a Chicago-based institutional investor.

Under the agreement, Fusion Capital has agreed to purchase up to $10 million of newly issued PhytoMedical stock, in $400,000 monthly amounts, over a period of up to 25 months based upon the market price of the common stock at time of purchase. However, PhytoMedical has the right to control the timing and the amount of stock sold, if any, to Fusion Capital. Further, and at the Company`s option, Fusion Capital can be required to purchase fewer or, subject to the satisfaction of certain conditions, greater amounts of common stock each month.

"We`re delighted to have the opportunity to work with Fusion Capital," states Mr. Harmel S. Rayat, a Director of PhytoMedical Technologies. "Fusion`s unique and innovative financing commitment will allow our Company to raise a significant amount of capital efficiently and on a cost effective basis from a single institutional investor.

"Now our management team can focus on PhytoMedical`s core research activities, expanding and accelerating the scope of our science and working towards developing clinically approved products for two of the most devastating disease states in America - diabetes and cachexia."

ABOUT PHYTOMEDICAL TECHNOLOGIES, INC.

PhytoMedical Technologies, Inc. (OTCBB:PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com .

To receive future press releases via email, please visit: http://www.PhytoMedical.com/Alerts-Index.asp .

To view the full HTML text of this release, please visit: http://www.PhytoMedical.com/IR/PressReleases/20050711-1.html .

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. Shareholder Communications Karley L. Smith, 800-611-3388 www.PhytoMedical.com

Copyright Business Wire 2005

[js200]

PhytoMedical: Revolutionäre Medizin
in Milliardenmärkten
Die Volkskrankheit Diabetes breitet sich weiter aus, innovative Medikamente sind gefragt. PhytoMedical Technologies (WKN: A0B79T) forscht unter anderem an solchen Wirkstoffen. Verlaufen die Forschungen weiter so positiv wie bisher, wird sich die Aktie vervielfachen.

Diabetes plagt weltweit viele Millionen Menschen - und es werden immer mehr. Innerhalb der nächsten Jahrzehnte soll sich weltweit die Zahl der erkrankten Menschen auf 360 Millionen mehr als verdoppeln. Studien zufolge wird 2050 jeder zehnte Amerikaner Diabetiker sein und somit auf die regelmäßige Insulin-Spritze angewiesen sein. Ungesunde Ernährung, Bewegungsmangel und die sich immer weiter ausbreitende Zahl der Menschen, die so leben, sorgen für das Wachstum der Krankenzahlen und bescheren der Pharmaindustrie einen Milliardenmarkt .

In diesem Bereich forscht auch PhytoMedical, unser heutiger Top-Tipp. Das Unternehmen beschäftigt sich vor allem mit der Forschung an und Weiterentwicklung von pflanzlichen Wirkstoffen, die gegen Krankheiten wie Diabetes, Fettleibigkeit oder auch die körperliche Auszehrung wirken sollen, die häufig der eigentliche Todesgrund bei AIDS- und Krebspatienten ist. Ein hochrangig besetztes Team von Wissenschaftlern forscht an einem Wirkstoff, der aus Zimtrinde gewonnen wird. Isoliert und charakterisiert wurden dabei verschiedene Polyphenol-Verbindungen, die im Reagenzglas-Versuch den Zuckerstoffwechsel um den Faktor 20 verbessert haben - ein für Diabetes-Patienten hoch interessanter Faktor. Frühere Studien mit menschlichen Probanden haben ergeben, dass bereits ein Gramm Zimt am Tag den Blutzuckerspiegel zwischen 18 und 29 Prozent senken kann, was die Ergebnisse der Untersuchungen von PhytoMedical bekräftigt.

Das Unternehmen strebt nun für seine Forschung den nächsten wichtigen Meilenstein an. Im nächsten Schritt sollen die aktiven Substanzen im Zimt synthetisiert und die positiven Wirkungen zunächst an Zellkulturen, später an Tieren und im letzten Entwicklungsschritt in Form klinischer Studien an Menschen erforscht und weiter entwickelt werden. Am Ende der Entwicklung soll ein klinisch getestetes Medikament stehen. Damit eröffnet sich PhytoMedical ein Milliarden-Markt . Institutionelle Investoren investierten kürzlich 10 Millionen Dollar in das Unternehmen und scheinen damit vom Erfolg überzeugt. PhytoMedical ist dadurch in der Lage, bestehende Forschungsprogramme zu finanzieren und weitere Forschungsprojekte aufzunehmen.

Bei PhytoMedical stimmt die Basis für ein spekulatives, aber dennoch solides Investment: Das jüngst akquirierte Eigenkapital zeigt das Vertrauen institutioneller Investoren in die Fähigkeiten des Unternehmens, hoch interessante Medikamente zu entwickeln. Zu diesem Vertrauen bei trägt nicht zuletzt die Kompetenz, die sich im wissenschaftlichen und im Management-Team des Unternehmens ballt. Der sehr interessante Markt, in dem das Unternehmen forscht, lässt bei Investoren Phantasie wachsen, sobald positive Ergebnisse aus den Forschungen bekannt werden. Tritt letzteres ein, explodieren die Kurse. Die Aktie ist nach mehrmonatiger Konsolidierungsphase nun wieder auf sehr interessantem Einstiegsniveau und damit ein klarer Kauf. Die von PhytoMedical in den letzten Monaten geschaffene Basis für den langfristigen Geschäftserfolg wird sich früher oder später auch im Aktienkurs widerspiegeln. Die alten Höchststände sollten auf Jahressicht wieder erreichbar sein. Kaufen bis 1,00 Euro.

Lesen Sie den kompletten Bericht zu PhytoMedical in der aktuellen Ausgabe von INVEST INSIDE. Melden Sie sich einfach unter http://www.invest-inside.net gratis an. Oder tragen Sie sich unten mit Ihrer E-Mail Adresse ein und Sie gelangen kostenlos zur aktuellen PDF-Ausgabe. Weiter erhalten Sie INVEST INSIDE dann ab sofort 90 Tage gratis zur Probe.

Nutzen Sie Ihre Chance und handeln Sie jetzt!

[js200]

09/01/2005 (11:46 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Edgar
08/29/2005 (09:55 ET) PYTO: Volume Spike; 132% > 20-adsv, Stock +5.56% - Knobias
08/29/2005 (09:38 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Edgar
08/29/2005 (09:15 ET) USDA Scientist Collaborating with PhytoMedical Receives Award for Outstanding Scientific Contribution - Business Wire
08/26/2005 (13:30 ET) PYTO: Volume Spike; 85% > 20-adsv, Stock -0.94% - Knobias

[clemania2000]

alles schön und gut, mir gefällt das profil dieser firma auch, aber wenn man sich das geschäft und die bilanz anschaut denke ich, dass die aktuelle bewertung weit mehr als angemessen ist.

169 mio marketcap. beinhaltet schon sehr viel phantasie oder?

hat keiner ne meinung hierzu?

clemania

[Albatossa]

[posting]17.874.555 von clemania2000 am 13.09.05 09:32:51[/posting]Ich denke auch das diese Aktie einwenig überteuert ist!

[js200]

09/26/2005 (16:31 ET) PYTO: Filed New Form SC 13D, Beneficial Ownership Disclosure - Edgar
09/16/2005 (17:04 ET) PYTO: PIPE-Related Registration Statement Declared Effective - Knobias
09/14/2005 (16:40 ET) PYTO: Filed New Form SB-2/A, SB `Shares for Cash` Registration - Edgar
09/01/2005 (11:46 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Edgar
08/29/2005 (09:55 ET) PYTO: Volume Spike; 132% > 20-adsv, Stock +5.56% - Knobias
---------------------------

Last Trade: 0.980 Change: 0.140 (+16.667%)
Previous Close: 0.840 Volume: 39,300
Bid: 0.830 Ask: 1.010
Today`s Open: 0.880 # of Trades: 6

Day High: 1.010 Day Low: 0.830
52 Week High: 1.500 52 week Low: 0.440
Market Cap: 166.56M Avg Daily Vol: 62,766
EPS: 0.01 PE Ratio: 84.000
Dividend: N/A Yield: N/A

------------------------------------

Business Summary: PhytoMedical Technologies Inc. is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

[CRJ200]

Hallo,

es ist irgendwie so ruhig geworden im Threat!?
Ist niemand mehr investiert oder seit ihr alle auf long und schaut deshalb nicht hier rein?
Hoffe, dass es bald wieder aufwärts geht mit der Aktie!!

Schönen Tag noch!!!

[clemania2000]

das teil ist viel zu teuer.
bin selbst verwundert dass es noch bei 90 cents an der otc steht.

es gibt 169 mio aktien....kein umsatz...kaum kapital....
wo ist hier phantasie?

kann einer mir nen plausiblen grund für nen einstieg nennen?

clemania

[js200]

10/19/2005 (11:06 ET) PYTO: Filed New Form 424B3, Rule 424-b3 Prospectus - Edgar
09/29/2005 (16:56 ET) PYTO: Filed New Form SC 13D, Beneficial Ownership Disclosure - Edgar
09/26/2005 (16:31 ET) PYTO: Filed New Form SC 13D, Beneficial Ownership Disclosure - Edgar
09/16/2005 (17:04 ET) PYTO: PIPE-Related Registration Statement Declared Effective - Knobias
09/14/2005 (16:40 ET) PYTO: Filed New Form SB-2/A, SB `Shares for Cash` Registration - Edgar

[CRJ200]

Hallo,

wo seht ihr das Unternehmen in den nächsten Jahren?
Wird es mit der Aktie wieder aufwärts gehen oder noch weiter bergab.
Bin noch investiert, habe aber ein Minus von 45% und bin am Überlegen, was ich machen soll, aussteigen mit dem Verlust oder noch abwarten. Viele News hört man ja in letzter Zeit nicht mehr von dem Unternehmen, oder?

MFG

[clemania2000]

hallo,
also ich hab anfang sept. oder so die kaufempfehlung gelesen und ein paar stücke gekauft. ist eigentlich nicht so meine art da ich schon seit längerem die finger von otc titeln lasse.
hab mir die bilanz angeschaut und bin sofort (auch mit verlust) raus.
die bude hat 169 mio aktien bisher herausgegeben, hat keinerlei werte und nur wenig bis keine kohle in der kasse.
für mich hat die fimra keinen wert, rechne damit wenn die kohle ganz ausgeht dass weitere aktien gedruckt werden.

und jetzt rechne mal die marktkapitalisierung aus....bei nem dollar warens 169 mio wert. ist das realistisch???

ich sage finger weg! auch wenn das ding durch zocker wieder steigt, da gibts überall weitaus interessantere titel.

clemania

[js200]

[posting]18.558.277 von CRJ200 am 03.11.05 16:52:02[/posting]10/27/2005 (17:10 ET) PYTO: Filed New Form 8-K, Material Event Disclosure - Edgar
10/24/2005 (10:26 ET) PYTO: Volume Spike; 14% > 20-adsv, Stock -6.25% - Knobias
10/24/2005 (09:15 ET) Dr. George Kraus, a Sloan Research Fellow, Part of PhytoMedical`s Growing Group of Collaborating Scientists Developing New Type 2 Diabetes Compound - Business Wire
10/19/2005 (11:06 ET) PYTO: Filed New Form 424B3, Rule 424-b3 Prospectus - Edgar
09/29/2005 (16:56 ET) PYTO: Filed New Form SC 13D, Beneficial Ownership Disclosure - Edgar

[js200]

[posting]18.638.127 von clemania2000 am 07.11.05 18:52:23[/posting]Last Trade: 0.760 Change: 0.030 (+4.110%)
Previous Close: 0.730 Volume: 53,100
Bid: 0.750 Ask: 0.770
Today`s Open: 0.660 # of Trades: 12

--------------------------------------------------------------------------------

Day High: 0.760 Day Low: 0.660
52 Week High: 1.500 52 week Low: 0.560
Market Cap: 140.02M Avg Daily Vol: 44,595
EPS: 0.01 PE Ratio: 73.000
Dividend: N/A Yield: N/A

[clemania2000]

will nicht sagen dass die aktie nicht mehr steigt, wie gesagt zocker können alles draus machen, aber FÜR MICH gibt es fundamental keinen grund die aktie zu kaufen oder zu halten.

siehst du gründe hierfür? wenn ja welche?

und was ist bei dieser marktkapitalisierung schon alles eingepreist?

allen investierten viel erfolg!

[clemania2000]

statt kursen poste ich lieber mal fakten:

Liquidity and Capital Resources

As at September 30, 2005, the Company had a cash balance of $95,538. The Company has financed its operations primarily through cash on hand, through loans from shareholders and proceeds from stock option exercises during the nine month period ending September 30, 2005.

Net cash flows used in by operating activities was $1,661,000 for the nine month period ending September 30, 2005, compared to net cash flows used of $97,353 for the same period in 2004, primarily due to an increase in investor relations expense, stock based compensation and research and development costs. The Company intends to seek additional funds from shareholders and third parties to finance the Company`s operations.

Net cash provided (used in) by financing activities was $1,419,000 for the nine months period ending
September 30, 2005 compared to $235,300 for the same period in 2004. The Company has financed its operations primarily from cash on hand, through loans from shareholders and proceeds from stock option and warrant exercises.

95.000 USD werden mit 90.000.000 marketcap. bewertet?

ich sag nur: es gibt noch viel platz nach unten.
mein kursziel sind 5 cents.

clemania

[Acute]

Ich bin im Moment mit einem Minus von 47% investiert. Soll ich die Aktie verkaufen oder nicht. Bin mir nicht so sicher. Nach dem letzten Posting von 0,05 Euro sollte ich doch verkaufen. Ich hätte die Kaufempfehlung lieber nicht lesen sollen!

[CRJ200]

Hallo Kollege,

dann gehts dir gleich wie mir. Hab mir auch nach der Kaufempfehlung das Unternehmen angeschaut und die Aktie gekauft! Hab im Moment auch ein Minus von 46% und bin mir auch nicht sicher, was ich machen soll! Zum Glück bin ich nicht, mit einer grossen Summe investiert! Werd glaub ich aber halten, denn irgendwann muss es ja wieder nach oben gehen!

MFG

[clemania2000]

leute, ich kann euch leider auch nicht sagen was momentan richtig ist.
mein kursziel würde für mich den fairen wert der firma darstellen, ohne richtig gute news sogar noch eher drunter.

da otc aber ein bißchen anders läuft kann es genauso gut sein, dass phyto wieder nach oben abhebt. aber mir fallen beileibe keine fundamentalen argumente dafür ein.

wenn jeder sich argumente sammelt für pro und contra, dann weiß man was zu tun ist.

mir fällt nichts positives ein und meine contras hab ich schon genannt:

-extrem hohe bewertung
-kein cash in der kasse (95.000 dollar)
- sie sprechen von milliardenmärkten, allerdings ist das ne übelst kleine klitsche und ich kann keine medizinischen fortschritte erkennen oder den beginn der verschiedenen testphasen

ich hoffe ihr werdet das richtige tun. schließe es auch nicht aus dass phyto wieder auf nen dollar steigt, wäre für mich bloß nicht logisch, aber das muss nichts heißen.

ich bin draußen und fühl mich wohl über dieses entscheidung. das einzige was mich ärgert war, blind investiert zu haben. typischer anfängerfehler, bzw. da hat mich die gier erwischt.

gruß
clemania

[clemania2000]

schaut euch mal die bilanz unter finance.yahoo.com an.

ich revidiere mein kursziel von 5 auf 1 cent.

heiße luft und NICHTS dahinter.
da hat ja jede ich ag in dtld. mehr zu bieten.

clemania

[Acute]

Ich bin auch raus. Bei 0,47 Euro. Der Tipp war echt super. Warum ich die Aktie gekauft habe, weiss ich bis heute nicht.

[SAT_2005]

Hi Leute,

Ich frage mich aber:
Weshalb ist die Aktie gestern um 6% gestiegen,
wenn alles so schlecht ist?

Nicht verwechseln: Ich frage mich auch wie Acute, weshalb Ich damals eingestiegen bin.
Ich möchte aber nicht mit Verlust (-45%) verkaufen.

Vielleicht tut sich noch was. Oder jemand weiß mehr (siehe 6% gestern)?

Eure Meinungen....

SAT

[clemania2000]

ja, 6% und warum?
kann ich dir auch nicht sagen, meine meinung ist nur, dass es keine fundamentalen gründe gibt diese aktie zu kaufen bzw. warum diese aktie eine solche bewertung hat.

für mich war das ein ganz billiger, schlecht recherchierter push eines börsenbriefes. übliche abzocke halt.

bin auch aus gier eingestiegen ohne nachzudenken, habs jedoch geschafft mit minimalen verlust rauszugehen, nachdem ich mir das profil, die bilanz etc. angeschaut habe.

jeder der blind bei sowas einsteigt hat einfach keine ahnung bzw. noch zu wenig schlechte erfahrungen gemacht.
mich hat auch die gier getrieben.

hab phyto noch auf meiner watchlist und verfolge es noch sporadisch, mal schauen...drück natürlich allen investierten die daumen noch heil rauszukommen.

ich vermisse hier allerdings ne sachliche diskussion mit fakten. es wird sich ja wohl jemand mit der firma beschäftigt haben wenn noch so viele drin sind, oder?

und das ich irgendwo recht habe zeigt der kurs ja. hab bei nem stand von 1 dollar auf die hohe marktkapitalisierung hingewiesen.

clemania

[clemania2000]

boah...was ist denn hier los?
die aktie explodiert ja förmlich. konnte keine news finden, vielleicht kommt ja noch was.

ich hab bisher immer nur fundamentale gründe für den rückgang angesprochen. mal schauen was noch so alles passiert.

clemania

[CRJ200]

Konnte leider auch keine news finden, aber ich hab beschlossen, dass ich noch investiert bleibe, in der Hoffnung, dass ich zumindest wiedermal das bekomme, was ich für das Teil bezahlt habe!

[clemania2000]

ich drück dir die daumen.
bin ja schon längst draußen und schau mir alles ganz entspannt an.
laut der bilanz finde ich dass die newslettermepfehlung ordentliche abzocke war.

wie auch immer, ganz egal warum es steigt, hauptsache es geht noch ein bißchen weiter.

nochmals so nen tag und du dürftest deinen einstiegskurs wieder sehen.

zumindest dann würd ich mir evtl. an deiner stelle überlegen nen (mentalen) stopp loss kurs zu setzen.

viel erfolg,

clemania

[js200]

Last Trade: 0.850 Change: 0.110 (+14.865%)
Previous Close: 0.740 Volume: 327,500
Bid: 0.850 Ask: 0.860
Today`s Open: 0.880 # of Trades: 58
-----------------------------------------

12/05/2005 (12:04 ET) Emerging Stock Report: Profits In The Plants - M2 Communications
12/05/2005 (10:35 ET) PYTO: Volume Spike; 14% > 20-adsv, Stock +16.22% - Knobias
12/02/2005 (16:22 ET) PYTO: Jumps +27.59%; Vol +480%; Last 90 Min of Trading - Knobias
12/02/2005 (16:05 ET) PYTO: Volume Spike; 168% > 20-adsv, Stock +27.59% - Knobias
11/15/2005 (09:51 ET) PYTO: New 52-Wk Low @ $0.550 dn 5.17% - Knobias

[js200]

Emerging Stock Report: Profits In The Plants

Monday , December 05, 2005 12:04 ET

Dec 05, 2005 (M2 PRESSWIRE via COMTEX) -- Diabetes affects 18.2 million people in the United States, or 6.3% of the population. The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. Regarded as the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year. Nearly one out of every ten health care dollars spent in the United States.

The Emerging Stock report is initiating coverage on PhytoMedical Technologies, Inc. (OTCBB:PYTO)(FWB:ET6) up 17% today. The company is an early stage research-based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds.

The company recently announced that it was pleased to acknowledge the ongoing efforts of Professor George A. Kraus and Dr. Yi Yuan, part of PhytoMedical`s growing team of collaborating scientists developing a new compound for type-2 diabetes. Mr. Harmel S. Rayat, President of PhytoMedical Technologies said "Our new compounds have been found to increase insulin sensitivity by activating key enzymes that stimulate insulin receptors while inhibiting those enzymes that deactivate them, basically resulting in insulin being more efficiently used by the body. In fact, in lab tests, we were able to increase sugar metabolism by a factor of twenty" PhytoMedical`s first plant derived compound named BDC-03, has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals. For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death. Cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

Ian Birrell

The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.

Get a Complimentary Subscription at www.emergingstockreport.com Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.

Safe Harbor

All material herein was prepared by the Emerging Stock Report (ESR) www.emergingstockreport.com based upon information believed to be reliable. The information contained herein is not guaranteed by ESR to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. ESR is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. ESR may receive compensation in cash or shares from independent third parties or from the companies mentioned.

ESR` s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. ESR will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ESR undertakes no obligation to update such statements

CONTACT: Ian Birrell e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD

[delange]

Phyto Medical:

Biotechjuwel mit explosiven
Blockbuster-Potenzialen

Das Biotechnologie-Unternehmen PhytoMedical Technologies (WKN: A0B79T) hat zwei potenzielle Blockbuster-Medikamente gegen Diabetes und Kachexie (pathologischen Gewichtsverlust) in der Pipeline. Die enormen operativen Fortschritte des Unternehmens und jüngste Konsolidierung der Aktie bieten spekulativen Anlegern explosive Kurschancen.


[IMAGE]Ein ganzes Heer von Forschern hat sich in den letzten Jahren mit der Forschung an Medikamenten gegen Krebs, AIDS oder Diabetes beschäftigt. Wirkliche Durchbrüche in der Bekämpfung der Krankheiten sind aber bislang ausgeblieben. Das kann sich bald ändern, denn PhytoMedical hat sich mit bemerkenswerten Studienergebnissen aufgemacht, den Kampf gegen lebensbedrohliche Volkskrankheiten aufzunehmen. Das Unternehmen konzentriert sich auf die Erforschung von Wirkstoffen aus natürlichen Substanzen. Den wichtigsten Wirkstoff, den das Unternehmen entdeckt hat, stammt aus einer Substanz, die in kaum einer gut ausgerüsteten Küche fehlt: Zimt.


Die Moleküle, die die Forscher des Unternehmens entdeckt haben, konnten bereits in verschiedensten Tests herausragende Ergebnisse in der Behandlung von Diabetes zeigen. Ein hieraus entstehendes Medikament hat Blockbuster-Potenzial. Über die beachtlichen Forschungsergebnisse wurde bereits in vielen angesehenen US-Publikationen berichtet, so etwa in den Magazinen Time und Forbes. Allein PhytoMedical hat es bislang nicht auf das Radar der Investoren geschafft. Dies wird sich ändern, wenn das Unternehmen weitere Fortschritte erzielt und nach und nach mit weiteren Forschungserfolgen von sich reden macht.


[IMAGE]Und die Chancen darauf stehen außerordentlich günstig: PhytoMedical kann im Rahmen einer Forschungskooperation mit den US-Behörden auf weit reichende staatliche Forschungsressourcen zurückgreifen, was einen immensen Wettbewerbsvorteil bedeutet. Diese unter der Bezeichnung CRADA laufenden Kooperationen haben für PhytoMedical einen Wert von vielen Millionen Dollar eingesparter Kosten. Derzeit befindet sich das Unternehmen in der Phase der Synthetisierung der Moleküle, die man zur Behandlung von Diabetes verwenden wird. Eine gelungene Synthetisierung sollte einer der nächsten fundamentalen Gründe für einen Kursanstieg der Aktie sein: Fortschritte bei der Entwicklung von Medikamenten-Projekten sorgen bei Biotech-Aktien regelmäßig für Kurssprünge.


Das Behandlungspotenzial von Diabetes ist hoch. Weltweit erkranken immer mehr Menschen an der Krankheit, die vor allem eine Folge der Lebensweise in modernen Zivilisationen ist. Nach letzten bekannten Zahlen leiden allein in den USA mehr als18 Millionen Personen oder mehr als 6 Prozent der Bevölkerung an Diabetes. Eine Zahl, die sich bis 2030 auf mehr als 30 Millionen erhöhen soll. Bereits jetzt fallen jährliche Kosten von 132 Milliarden Dollar pro Jahr an. PhytoMedical kann sich bei einer erfolgreichen Entwicklung des Medikamentes einen milliardenschweren Markt sichern.


[IMAGE]Und es gibt noch einen zweiten Blockbuster-Kandidaten bei PhytoMedical, der im Unternehmen als BDC-03 bezeichnet wird: Dieser Medikamentenkandidat hat bisher exzellente Studienergebnisse bei der Bekämpfung von Kachexie geliefert. Darunter wird eine starke körperliche Auszehrung aufgrund massiver Stoffwechselstörungen verstanden. Die Folgen sind hohe Gewichtsverluste durch Abbau von Fett- und Muskelgewebe, Anämie, Schwächungen des Immunsystems und ein Schwächezustand, der die Lebensqualität des Erkrankten weiter einschränkt und die Behandlung der eigentlichen Erkrankung massiv erschwert. Tatsächlich ist Kachexie in vielen Fällen die eigentliche Todesursache, wenn Krebspatienten sterben – nicht das bösartige Tumorgewebe.


[IMAGE]Die Forschungen mit PhytoMedicals BDC-03 haben ergeben, dass die Substanz eine Reduzierung des Körperfettanteils sowie des Cholesterins bewirkt, womit es auch in der Behandlung von übergewichtigen Patienten eine Option werden könnte. Darüber hinaus, bewirkt die Substanz einen Aufbau der Muskelmasse. Derzeit befindet sich PhytoMedical in dem Prozess der Isolation der für die Wirkung verantwortlichen bioaktiven Substanzen. Für die weiteren Kachexie-Forschungen zeichnet sich eine ähnlich positive Entwicklung wie beim Diabetes-Projekt ab.


Die Aktie ist bislang vom Markt noch unentdeckt. Sobald breitere Anlegerkreise auf die hohen Forschungspotenziale von PhytoMedical aufmerksam werden, wird der Aktienkurs die aktuellen Regionen schnell verlassen. Zudem sind Anleger, die jetzt einsteigen, nicht alleine: PhytoMedicals Vorstandsvorsitzender hat selbst 2,5 Millionen Euro aus eigenem Vermögen in das Unternehmen investiert. Mit einem Venture-Capital-Fonds aus Chicago besteht zudem eine Vereinbarung für den Erwerb von PhytoMedical-Aktien im Wert von bis zu 10 Millionen Dollar im Zuge von Kapitalerhöhungen. Die Weichen für eine erfolgreiche Finanzierung der Forschungsprojekte sind damit auf eine solide Basis gestellt.

[IMAGE]Fazit: Die Potenziale, die in der PhytoMedical-Aktie schlummern, sind riesig. Die zu erwartenden positiven Nachrichten aus der Forschungspipeline werden für drastische Kurssprünge sorgen. Äußerst positiv auf das Gesamtbild wirken sich die Investitionen des Vorstandvorsitzenden und Venture-Capital-Fonds sowie die enormen Wettbewerbsvorteile der Forschungskooperation mit den US-Behörden aus. Insgesamt also ein Mix, der für explosive Kursgewinne steht.


Auch charttechnisch hat die Aktie den Ausbruch aus dem seit Ende August 2005 anhaltenden Abwärtstrend geschafft und den Turnaround vollzogen. Hier bieten sich kurzfristige Rebound-Chancen bis zu dem Kurständen vom September 2005 um 1,10 USD, was auf aktuellem Niveau einer 40%-Chance entspricht. Die Aktie hat mittelfristig Potenzial bis zu den Höchstständen vom Mai dieses Jahres um 1,50 USD. Nach der drastischen Konsolidierung der letzten Monate ist das Papier daher auf aktuellem Niveau sowohl für kurzfristig orientierte Trader als auch für mittelfristig orientierte Value-Investoren ein glasklarer Kauf.


PhytoMedical Technologies
Frankfurt: WKN A0B79T
New York: PYTO

[SAT_2005]

Hi,

endlich tut sich was:

Berlin (ots) - Im aktuellen PENNYSTOCK REPORT empfehlen die Analysten die PhytoMedical Technologies (WKN: A0B79T / ISIN: US71944A1079), ein Biotechunternehmen, das sich dem Kampf gegen Kachexie und Diabetes verschrieben hat. Bisher konnten erfolgreiche Studienergebnisse bekannt gegeben werden.

Im Time- als auch im Forbes-Magazin werden die Forschungsergebnisse von PhytoMedical Technologies bereits hoch angesehen. Unterstützt wird das Unternehmen in den USA aktuell durch eine Forschungskooperation mit US-Behörden. Dadurch können Forschungsprojekte vorangetrieben werden. Das Forschungsprojekt für Diabetes forscht bereits seit 10 Jahren und steht kurz vor dem Durchbruch - allein der Markt für Diabetes wäre für PhytoMedical gigantisch!

Auch im Kampf gegen die Kachexie ist das Unternehmen tätig. Aktuell besteht die Chance, ein mögliches, schon bald hergestelltes Medikament mit dem Namen BDC-03, mit Blockbusterpotenzial in einem absoluten Wachstumsmarkt zu etablieren. BDC-03 reduziert aktuell den Körperfettanteil und das Cholesterin, baut jedoch auch gleichzeitig Muskelmasse auf und stärkt somit auch den Körper vor Kachexie.

Sollte es tatsächlich zur baldigen, positiven Zulassung einer der beiden Medikamente kommen, wäre eine Verdoppelung des Aktienkursen nicht auszuschließen. Der Vorstand von PhytoMedical Technologies scheint sich dieser Chance ebenfalls bewusst zu sein - Nicht ohne Grund hat er erst kürzlich 2,5 Mio. Euro aus seinem Privatvermögen in das Unternehmen investiert!


Fazit

Die PhytoMedical Technologies hat das Zeug zwei Blockbuster zu bringen! Allein eine Zulassung in nächster Zeit würde bereits für einen enormen Kursanstieg sorgen. Spekulative Anleger positionieren sich frühzeitig! Die Analysten des PENNYSTOCK REPORTs stufen den Wert auf Kaufen mit einem Kursziel von 1,70 EUR.

Lesen Sie den vollständigen Report unter www.pennystockreport.de!

Grüße
SAT

[DoublePenetration]

ziemlich ruhig hier...

Heute Kaufempfehlung von Penystcok Report für PhytoMedical!!!

Kachexie
Krankhafte, starke Abmagerung – Body Mass Index von unter 18!

Unter Kachexie versteht man eine Auszehrung des Körpers. Kachexie tritt vor allem bei fortgeschrittenen Krebser- krankungen auf und ist gekennzeichnet durch Abmagerung, Kräfteverfall und zunehmende Störung der Organfunktionen. Heute weiß man, dass Krebszellen selber Substanzen produzieren können, die zur Kachexie führen, allerdings können auch körpereigene Reaktionen auf den Tumor die Ursache für die Kachexie sein. Die Kachexie selber kann wiederum die Müdigkeit und Erschöpfung des Erkrankten verstärken und unterhalten. Ursachen, die ebenfalls zur Kachexie führen können, sind unzureichende Nahrungs- aufnahme, spezifische Tumortherapien oder organische Störungen, wie zum Beispiel Hindernisse im Verdauungstrakt (z.B. durch einen Tumor) sein. Der behandelnde Arzt wird, je nach zugrunde liegender Ursache, versuchen, der Kachexie entgegenzuwirken. Dies kann zum Beispiel in der Beseitigung oder der Umgehung eines Hindernisses in der Verdauungs- passage bestehen, dies kann in der Beseitigung einer therapiebedingten Übelkeit liegen oder in der Gabe hochkalorischer Astronautenkost. Weitere Ursachen können, neben den chronischen Krankheiten wie Krebs oder AIDS, andauernde Hungerzustände, Ess- störungen, anhaltende Erkrankungen des Magen-Darm-Trakts sowie Kachexie infolge von chronischer Herzinsuffizienz oder Alterserscheinungen.

Im Gegensatz zur Inanition (Abmagerung) werden bei der Kachexie nicht nur die Speicherfettdepots, sondern auch das Baufett und die Muskulatur abgebaut. Das Knochenmark wandelt sich in Gallertmark um, auch bei anderen Organen kommt es zu Atrophien und Funktionsausfällen. Lebensbedrohlich wird der Zustand, wenn der Herzmuskel angegriffen wird. Kachexie führt damit bald zu irreversiblen Veränderungen und schließlich zum Tod.


Das Kachexie-Syndrom bei Tumorpatienten

Die Kachexie ist ein häufiger Befund bei Tumorerkrankungen. Oft geht ein Gewichtsverlust der Tumordiagnose voraus. Im Gegensatz zum Fastenzustand, bei dem zunächst Fett mobilisiert wird, werden bei Kachexiepatienten Fett- und Muskelproteine gleichermaßen abgebaut. Mangelernährte Tumorpatienten leiden häufiger unter Komplikationen wie Wundheilungsstörungen, Infektionen, und Sepsis. Ferner ist die Verträglichkeit und der Erfolg von Operationen, Chemo- und Radiotherapie reduziert. Die Sterblichkeitsrate ist bei Patienten mit Tumorkachexie mit 30% erhöht.

Die Krebskachexie ist gekennzeichnet durch:


• Gewichtsverlust vor allem von subkutanem Fettgewebe
• Gewichtsverlust von Muskelmasse
• Anorexie u. Sattheitsgefühl
• Schwäche
• Anämie und Müdigkeit
• Ödeme
• Immunschwäche
• Verminderte motorische Funktion
• Verminderte Lebensqualität


Patienten mit Tumoren des Magen-Darm-Traktes und der Lunge sind häufiger von Mangelernährung bzw. Unterernährung betroffen, als Patienten mit anderen Tumorarten. Die Entstehung der Tumorkachexie ist in der Regel multifaktoriell. Ursächlich beteiligt sein können wie bereits erwähnt Stoffwechselstörungen und tumorbedingte Passagebehinde- rungen sowie Nebenwirkungen der Tumortherapie und psychische Belastungen.

Tumor- induzierter Gewichtsverlust tritt bei fast allen soliden Tumorerkrankungen (u. a. Prostata-, Pankreas- und Brustkrebs) auf. Schätzungen zufolge sind ca. 75 Prozent aller onkologischen Patienten zum Diagnosezeitpunkt bereits unterernährt. Diese Tatsache ist von klinischer Relevanz: es ist seit langem bekannt, dass nicht weniger als 20 Prozent aller Patienten allein an den Folgen einer Unterernährung und nicht an den direkten Folgen der Tumorerkrankung sterben. Ebenfalls kann schon eine Gewichtsreduktion um nur 5 Prozent das Ansprechverhalten auf Therapien negativ beeinflussen. Die durchschnittliche Überlebensdauer bei Patienten mit Gewichtsverlust ist deutlich niedriger als bei Patienten ohne ungewollten Gewichtsverlust. Das Kachexiesyndrom wird als ein Anzeichen für eine verschlechterte Prognose betrachtet, wobei sich eine ausgeprägte Form der Kachexie ungünstig auf die Überlebensdauer auswirkt. Eine frühzeitige, begleitende Ernährungs- therapie kann helfen, Unterernährung und Gewichtsverlust vorzubeugen und die Therapiechancen zu erhöhen.

Ein Biotechunternehmen, das sich eingängig mit der Kachexie, mit Diabetes und mit anderen schweren Erkrankungen beschäftigt hat, möchten wir Ihnen heute vorstellen. Allein für den Kampf gegen Diabetes und die oben beschriebene Kachexie befinden sich aktuell zwei Medikamente in der Pipeline:



- PhytoMedical Technologies Inc. (WKN: A0B79T / ISIN: US71944A1079) -

- handelbar in Frankfurt & Stuttgart -

[LastDrow]

Die Kurse werden doch in den USA gemacht, dort steht das Teil bei 1$. Hätten wir hier in Deutschland also ca. 10 % Vorschußlorbeeren.
Das kann doch nicht gerechtfertigt sein !?

[DoublePenetration]

PhytoMedical Technologies Inc.
Kampf gegen Kachexie & Diabetes!
Unsere heutige Empfehlung PhytoMedical Techno- logies (WKN: A0B79T / ISIN: US71944A1079) ist ein Biotechunternehmen, das sich dem Kampf gegen Kachexie und Diabetes verschrieben hat. Bisher konnten erfolgreiche Studienergebnisse bekannt gegeben werden. Der Schwerpunkt der Forschung bei PhytoMedical Technologies basiert auf organischen, natürlichen Produkten - so wurde z.B. einer der wichtigsten Wirk- stoffe des Unternehmens aus Zimt gewonnen.

Im Time-Magazin als auch im Forbes-Magazin werden die Forschungsergebnisse von PhytoMedical Technologies bereits hoch angesehen. In Deutschland und Europa ist das Unternehmen mit den etwas anderen Forschungsmethoden noch nahezu unbekannt. Unterstützt wird das Unternehmen in den USA aktuell durch eine Forschungskooperation mit US-Behörden. Durch diese “staatliche Förderung“ können Forschungsprojekte der PhytoMedical Technologies vorangetrieben werden. Aktuell forscht das Unternehmen an der Synthetisierung der Moleküle für die Behandlung von Diabetes. Das Forschungsprojekt für Diabetes forscht bereits seit 10 Jahren und steht kurz vor dem Durchbruch – allein der Markt für Diabetes wäre für PhytoMedical gigantisch!

Aktie:
PhytoMedical Technologies Inc.

Der Markt für Diabetes
Allein der Markt der Diabetiker ist enorm. Es gibt nicht nur Millionen von Menschen mit Diabetes TYP I (Jugenddiabetes), die sich mit ihren täglichen Insulininjektionen herumquälen müssen, darüber hinaus gibt es auch noch über 150 Millionen Diabetiker des TYPs II (Altersdiabetes, also Opfer einer globalen Pandemie, die durch schlechte Essgewohnheiten und mangelnde Bewegung hervorgerufen wird), die kein Insulin nehmen, weil sie es sich nicht spritzen wollen. Zur Kontrolle ihres Blut- zuckers greifen diese Typ II-Diabetiker auf alle möglichen anderen Medikamente zurück. Bei einigen führt die zerstörerische Krankheit zu Spätfolgen wie Behinderung, Erblindung oder Amputation.

Nach Schätzungen des US-Diabetesverbandes American Diabetes Association betrug die Zahl der Diabetiker im vergangenen Jahr weltweit 145 Millionen. Das US-Center for Disease Control berichtet, dass Diabetes in den USA seit 1991 um 61% angestiegen ist, und geht davon aus, dass es 7 Millionen nicht diagnostizierte Fälle von Diabetes gibt. Der Markt für Diabetes-Therapien hat allein in den USA ein Volumen von über 6 Milliarden Dollar pro Jahr.

Neben dem Wirkstoff gegen Diabetes ist das Unternehmen, wie bereits erwähnt, auch tätig im Kampf gegen die Kachexie. Aktuell besteht die Chance, ein mögliches, schon bald hergestelltes Medikament mit dem Namen BDC-03, mit Blockbusterpotenzial in einem absoluten Wachstumsmarkt zu etablieren. BDC-03 reduziert aktuell den Körperfettanteil und das Cholesterin, baut jedoch auch gleichzeitig Muskelmasse auf und stärkt somit auch den Körper vor Kachexie-

Ausblick
Sollte es tatsächlich zur baldigen, positiven Zulassung einer der beiden Medikamente kommen, wäre eine Verdoppelung des Aktienkursen nicht auszuschließen. Der Vorstand Mr. Rayat von PhytoMedical Technologies scheint sich wohl dieser Chance ebenfalls bewusst zu sein - Nicht ohne Grund hat er erst kürzlich 2,5 Mio. Euro aus seinem Privatvermögen in das Unternehmen investiert! Des weiteren besteht eine Vereinbarung mit einem Venture-Capital-Fonds aus Chicago, der Fusion Capital, gegen Einlage von 10 Mio. USD, Aktien im Zuge einer Kapitalerhöhung zu beziehen – die zukünftige Finanzierung sei somit ebenfalls vorerst gesichert!

Fazit
Biotechunternehmen können allein mit einem Produkt bzw. Medikament von heute auf morgen zum Highflyer oder Outperformer werden. Unsere heutige Empfehlung PhytoMedical Technologies (WKN: A0B79T / ISIN: US71944A1079) hat dagegen das Zeug zwei Blockbuster zu bringen! Mit einem Medikament ge- gen Diabetes als auch einem Medikament gegen Kachexie ist das Unternehmen bestens positioniert! Allein eine Zulassung in nächster Zeit würde bereits für einen enormen Kursanstieg sorgen. Spekulative Anleger positionieren sich frühzeitig! Wir stufen den Wert auf Kaufen mit einem Kursziel von 1,70 EUR.

[js200]

Last Trade: 1.250 Change: -0.110 (-8.088%)
Previous Close: 1.360 Volume: 358,300
Bid: 1.240 Ask: 1.260
Today`s Open: 1.350 # of Trades: 161

[js200]

New Independent Three Year Study Shows That Cinnamon ``Can Relieve Diabetes`` by Lowering Blood Sugar Levels
via COMTEX

January 30, 2006

VANCOUVER, British Columbia, Jan 30, 2006 (BUSINESS WIRE) --

PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6):

-- PhytoMedical Continues the Development of a New Cinnamon Derived Compound for Type-2 Diabetes

-- Certain Compounds in Cinnamon Lower Blood Sugar Levels by an Average of 18 to 29% without Side Effects

PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), an early stage research based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today commented on a new three year study carried out by the Universiti Teknologi Malaysia which reported that cinnamon can relieve diabetes by lowering blood sugar levels. This study confirms previous findings that cinnamon has positive effects on type-2 diabetes, which affects over 18 million people in the US alone.

"The independent research findings of Dr. Mohammad Roji Sarmidi, at the Universiti Teknologi Malaysia, reinforces our efforts to develop a new synthetic compound for type-2 diabetes derived from cinnamon," states Mr. Harmel S. Rayat, President and CEO of PhytoMedical Technologies. "We already know from numerous studies and reports, including those conducted by our own collaborating scientists at the USDA`s Agricultural Research Service, that cinnamon contains certain molecules responsible for reducing blood sugar levels. Our job now is to reproduce mother nature`s handiwork in the lab, without some of the toxic substances she`s added, such as cinnamaldehyde and related compounds, which could be toxic if consumed in high levels or for an extended period of time."

Mr. Rayat concludes, "Just as Aspirin(R), which now generates $29 billion in sales annually, was synthesized from the bark of willow trees, and Taxol(R) was synthesized from the Pacific yew tree, our goal is to synthesize those select blood sugar reducing cinnamon molecules in the lab and eventually develop a pharmacologically approved compound that could be ingested as a pill or added to foods or beverages, with the end result being lowered blood sugar levels through more efficient use of the body`s naturally produced insulin."

We are not affiliated with either Dr. Mohammad Roji Sarmidi or the Universiti Teknologi Malaysia.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year -- nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com.

To receive future press releases via email, please visit:

http://www.PhytoMedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit:

http://www.PhytoMedical.com/IR/PressReleases/20060130-1.html

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company`s products, technical problems with the Company`s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company`s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company`s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company`s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE: PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. Karley L. Smith, 800-611-3388 www.PhytoMedical.com

Copyright Business Wire 2006

Print story

Current Quote

OBB: PYTO
Specialized Health Services

Last: 1.320
Change: -0.040
Volume: 214,106
Day High: 1.400
Day Low: 1.320



First Alert News
Get real-time PYTO release alerts by entering your email address below.

[LastDrow]

Kann das einer mal bitte in wenige Worte übersetzen ?

[LastDrow]

1,48 $

Nicht mehr weit bis 1,50 § !!
Nächstes KZ 1,70 $ oder was ?

[LastDrow]

Schluß auf Tageshoch 1,50 $ !!!

Das hieße ein umgerechneter Kurs von ca. 1,23 EUR !

[seeensation]

1,50 $ = 1,245 € !!!

Dollarkurs bei 1,205 !

Gruß

In D akt. deutlich unter pari...
Wird sich aber mit USA-Start gleich anpassen...

[arubabeachclub]

USA jetzt schon 1,53

[arubabeachclub]

und Frankfurt bei 1,29 €

[arubabeachclub]

... und jetzt ist Frankfurt bei 1,32 €

[arubabeachclub]

Und im Amiland geht es weiter nach oben.
Schon 1,58 USD kurz nach Eröffnung

[SAT_2005]

Kurs schlagartig gefallen

Weiß jemand warum?

Gibt`s (schlechte) News?
Oder Gewinnmitnahmen?

Grüße
SAT

[KasiKman]

Naja, günstige Gelegenheit nochmal billig einzusteigen. Danke

[KasiKman]

New Independent Three Year Study Shows That Cinnamon ``Can Relieve Diabetes`` by Lowering Blood Sugar Levels
Monday January 30, 9:15 am ET

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 30, 2006--PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; FWB:ET6):

* PhytoMedical Continues the Development of a New Cinnamon Derived Compound for Type-2 Diabetes
* Certain Compounds in Cinnamon Lower Blood Sugar Levels by an Average of 18 to 29% without Side Effects

PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; FWB:ET6), an early stage research based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds, today commented on a new three year study carried out by the Universiti Teknologi Malaysia which reported that cinnamon can relieve diabetes by lowering blood sugar levels. This study confirms previous findings that cinnamon has positive effects on type-2 diabetes, which affects over 18 million people in the US alone.

"The independent research findings of Dr. Mohammad Roji Sarmidi, at the Universiti Teknologi Malaysia, reinforces our efforts to develop a new synthetic compound for type-2 diabetes derived from cinnamon," states Mr. Harmel S. Rayat, President and CEO of PhytoMedical Technologies. "We already know from numerous studies and reports, including those conducted by our own collaborating scientists at the USDA`s Agricultural Research Service, that cinnamon contains certain molecules responsible for reducing blood sugar levels. Our job now is to reproduce mother nature`s handiwork in the lab, without some of the toxic substances she`s added, such as cinnamaldehyde and related compounds, which could be toxic if consumed in high levels or for an extended period of time."

Mr. Rayat concludes, "Just as Aspirin®, which now generates $29 billion in sales annually, was synthesized from the bark of willow trees, and Taxol® was synthesized from the Pacific yew tree, our goal is to synthesize those select blood sugar reducing cinnamon molecules in the lab and eventually develop a pharmacologically approved compound that could be ingested as a pill or added to foods or beverages, with the end result being lowered blood sugar levels through more efficient use of the body`s naturally produced insulin."

We are not affiliated with either Dr. Mohammad Roji Sarmidi or the Universiti Teknologi Malaysia.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; FWB:ET6), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical`s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03`s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body`s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year -- nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com.

[SVA]

Sieht doch schon wieder klasse aus!!!
#KKman
Warst oder bist schon dabei, oder erst durch Deinen Biotech-Thread aufmerksam?

[arubabeachclub]

Im Amiland scheints heute wieder up zu gehen

[KasiKman]

@SVA
Bin durch den Thread draufgekommen und hab mir sozusagen die Rosine rausgepickt. Danke nochmals für den Tipp.

[lindgreen]

Im Moment geht es ja nur noch abwärts, was ist denn da los.... Hoffe wir haben bald wieder Boden unter den Füßen...

[LastDrow]

Weiß jemand warum der Wert die letzten Tage so Federn lassen mußte ? Habe keine News gefunden !
Sind die Zocker raus ??

Ich hoffe der 1$ hält, sonst werde ich aucxh die notbremse ziehen !

[KasiKman]

so, es zieht wieder an...

[LastDrow]

Kann Dein Posting leider nur ironisch verstehen !
+ 0,90 % kann man nicht ernst nehmen !

Es sieht eher nach einer kurzfristigen Seitwärtsbewegung aus. (Nach der es hoffentlich wieder aufwärts geht)

Wiederhole meine Frage nach den Gründen für den starken Kursverfall nochmal. Weiß jemand ob s dafür Gründe gab/gibt ??

Danke !

[KasiKman]

Offizielle Nachrichten habe ich jedenfalls keine gefunden.
Plausible Erklärung- Gewinnmitnahmen.

[arubabeachclub]

[posting]20.189.319 von LastDrow am 13.02.06 21:49:44[/posting]Vielleicht haben da einige Gewinne mitgenommen. Die Aktie ist in den letzten Wochen ja ordentlich nach oben ausgebrochen.
NAchdem die vorläufige Decke erreicht war, sind erst mal die Zocker raus und dann die, die erst mal Gewinne sichern um billiger wieder rein zu kommen.
Du hast ja gesehen, dass einige ihre persönliche Stops haben.

[SVA]

...denke auch so und diese woche gibts auf jeden fall mal wieder + 10%!!!

[spontanix]

mag sein das dies schon mehrfach genannt wurde ( habe die pyto threads nicht alle gelesen), aber der punkt wirkstoffe aus pflanzen zu finden/gewinnen ist der weg!
wenn man zb bedenkt das tamiflu den ursprung im sternanis hat
ich denke die firma tut gutes und das nicht nur fürs depot( würds sogar als "very-long"-kandidat nehmen)

[LastDrow]

[posting]20.210.807 von spontanix am 15.02.06 07:24:14[/posting]Das ist der Grund warum ich investiert bin !
In pflanzlichen Wirkstoffen steckt enormes Potential. Das wußten die Leute schon früher. Leider wurde diese dann als Hexe verbrannt ! Und das Wissen ging verloren. Jetzt wirds langsam wiederentdeckt. Eine Firma, die da von Anfang an Patente sichert gehört zu den Gewinnern von morgen !
Trotzdem man Phyto als Long Invest sehen sollte, sollte man nicht jeden verlust hinnehmen, auch bei einem Longinvest werden 50 % minus nur durch 100 % Gewinn zu gerade mal +/- Null. Lieber laß ich mich ausstoppen und steige später wieder ein !

Hoffe immernoch das der 1 $ hält !

[arubabeachclub]

News out:


Press Release Source: PhytoMedical Technologies, Inc.


PhytoMedical to Expand Its Research Activities to Include New Drug Candidates
Wednesday February 15, 9:15 am ET


VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 15, 2006--PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; FWB:ET6):
In Addition to Its Ongoing Diabetes and Cachexia Research, PhytoMedical Now Plans to Expand Its Activities to the Identification, Research and Development of Additional Plant Derived Compounds for Obesity, Cancer and Alzheimer`s Disease
PhytoMedical Technologies, Inc. (OTCBB:PYTO - News; FWB:ET6), an early-stage research-based biopharmaceutical company focused on the identification, development, and eventual commercialization of innovative plant-derived pharmaceutical and nutraceutical compounds, today announced its plans to actively pursue the research and development of additional plant derived compounds targeting obesity, various types of cancer and Alzheimer`s disease, among others.

Presently, twenty of the best-selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants. In fact, of the 250,000 species of higher plants found on earth, less than 15% have been investigated for bioactive compounds. As a result, an estimated 300 new drugs of worldwide importance, worth over $150 billion, still remain to be discovered.

"Despite a record amount of capital going into new drug development, advances in high through put screening technologies and genomic research, very little has come about in the way of new drug discoveries from the pharmaceutical industry," states Mr. Harmel S. Rayat, President and CEO of PhytoMedical Technologies. "In fact, last year the FDA approved only 20 news drugs, down from 36 in 2004.

"Over the years, scientists have become better at deciphering the structure of chemicals found in nature, resulting in some of the world`s biggest selling drugs, including some that today bring in as much as $25 billion a year to pharmaceutical companies. Some of the recent discoveries include the clinical trials of a drug derived from the vegetable cicada for multiple sclerosis and a phase II trial to evaluate the efficacy of curcumin (an ingredient in the spice, tumeric) in patients with advanced pancreatic cancer."

Mr. Rayat concludes, "Research regarding the possible identification of new drug compounds derived from natural sources is full of potential. We believe that we are well positioned to expand our existing research and development efforts in this area to the possible identification and development of new drug compounds derived from natural sources to deal with a variety of health issues including obesity, various types of cancer and Alzheimer`s disease, among others."

[KasiKman]

Warum ist es hier so ruhig? Freut sich keiner hier über die Wende und ein gesundes Kurswachstum???

[LastDrow]

Scheinbar wurden einige beim letzten Kursrückgang rausgespült...

[KasiKman]

Naja, dann kann es ja nur noch aufwärts gehen

[lindgreen]

USA +14,71 %, das ist doch mal was!!
Endlich aml wieder aufwärts mein Baby!

[SAT_2005]

Gibt es News????

Grüße
SAT

[LastDrow]

10-Mar-2006
Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
The following exhibits are furnished as part of this report:
Exhibit Number
Description
10.1
Amendment and extension of Cooperative Research Agreement with the United States

Department of Agriculture`s Agricultural Research Service and Iowa State University


Die Vereinbarungen mit dem Staat über Forschungsprojekte wurden verlängert (wenn ich das jetzt richtig verstanden habe...)
Nichts weltbewegendes, aber allemal nicht schlecht !

[KasiKman]

Wo kam der Bericht? Hört sich sehr gut an....

[LastDrow]

http://biz.yahoo.com/e/060310/pyto.ob8-k.html

[SVA]

Geht doch wieder nach oben!!! Denke nach wie vor wir haben hier ein gutes Invest. Auf gehts!

[SVA]

Es geht weiter!!! Wir sollten man wieder Leben in den Thread bringen!!

[LastDrow]

Genau !
Es geht wieder vorwrts.
Jetzt mu nur noch die 1,50 $ nachhaltig berwunden werden....

Ein paar gute Meldungen drften reichen !
Und hier ist schon eine:
http://biz.yahoo.com/bw/060321/20060321005408.html?.v=1

[LastDrow]

Aktuell 1,38 !!

Keiner mehr investiert ??

[KasiKman]

immer noch dabei

[Elsner]

Antwort auf Beitrag Nr.: 20.966.126 von LastDrow am 27.03.06 21:19:03

I'm still standing (...sorry, must be: I'm still holding!)

[SVA]

Antwort auf Beitrag Nr.: 20.966.870 von Elsner am 27.03.06 22:13:16

... und weiter gehts !!! Phytomedical, gute Aktie, gute Kurse.

[SVA]

OTCBB
PYTO / USD 1,39
2.500 +0,090
+6,92 17:59:41
03.04.2006

[LastDrow]

Neuer CEO ??

http://biz.yahoo.com/bw/060403/20060403005776.html?.v=1

[KasiKman]

Was ist hier los?
Lauter good news und das Scheiss Papier gibt Tag für Tag ab.

[bonjabi]

Trading-Insider
Biotechshooter mit immensen Blockbusterpotenzialen vom 11.04.2006

-------------------------------------------------------------------------------------------------------------------------------

Phyto Medical:

Kaufen! | Kurs: 0,95 Euro |

Immenses Blockbuster-Potenzial
An der Börse können Anleger viele Fehler machen, große wie kleine. Ein riesengroßer Fehler wäre es, Zukunftsbranchen bzw. deren aussichtsreiche Vertreter im Depot zu ignorieren. PhytoMedical Technologies (WKN: A0B79T) ist ein solcher Vertreter in der Biotechbranche.


Und nach fast einhelliger Meinung der Experten ist die Biotechnologie eine boomende Branche. Sie ist in der Lage, das dicke Loch an Neuentwicklungen zu füllen, das bei den großen Pharmaunternehmen nach vielen Forschungsflopps entstanden ist. Pharmaunternehmen zahlen viel Geld an oftmals hochspezialisierte Biotechunternehmen, die mit bahnbrechenden Entdeckungen aufwarten können. Viele Biotechriesen sind so entstanden, die heute in den bedeutenden Indizes der US-Börsen notieren.


Und die Zukunft, soviel ist sicher, wird weitere Stars hervorbringen. Dies auch vor dem Hintergrund, dass viele potenzielle Medikamentenwirkstoffe noch gar nicht entdeckt sind. Allein im weltweiten Reich der Pflanzen sind unter rund 250.000 Pflanzenarten gerade einmal 15 Prozent auf biologisch wirksame Stoffe untersucht. Dennoch hat das gereicht, um absolute Bestseller wie Aspirin zu entdecken, das seinen Ursprung in einer Baumrinde hat.


In einem solchen Raster bewegt sich PhytoMedical Technologies. Das amerikanische Unternehmen ist aber nicht nur aufgrund der Forschungsprojekte interessant, sondern auch aufgrund der Köpfe hinter dem Unternehmen. Das wichtigste Kapital von forschenden Unternehmen ist das Know-How des Managements und des wissenschaftlichen Teams. Und da hat PhytoMedical bisher absolut überzeugt. CEO Greg Wujek, früherer Senior Manager bei Forest Laboratories, war eine der treibenden Kräfte bei Andrx Laboratories, die in einem 1,9 Milliarden Dollar schweren Deal von Watson Pharmaceuticals aufgekauft wurden. Unter den Wissenschaftlern, mit denen PhytoMedical zusammen arbeitet, sind führende Experten, vielfach ausgezeichnet und deren Arbeiten bereits Gegenstand von zahllosen Veröffentlichungen in renommierten Fach- und Publikumsmagazinen war. Vor allem zu nennen ist hier Dr. George Kraus.


Die Projekte, an denen PhytoMedical forscht, haben allesamt das Potenzial, zu hoch interessanten Blockbustern zu werden. Auch wenn die Entwicklungsprozesse noch einige Zeit in Anspruch nehmen werden, ist dies für Anleger kein Grund, die Hände in den Schoß zu legen und zu warten. Im Gegenteil: Typisch für Biotechunternehmen ist, dass die Kursentwicklung der Aktien sich sehr stark an den Forschungsergebnissen orientiert. Werden Fortschritte erzielt oder kann ein Unternehmen Forschungspartner an Bord holen, wächst der Wert des Forschungsprojektes – die Aktien springen dann nicht selten stark nach oben. So lassen sich mit Biotechaktien starke Kursgewinne erzielen, lange bevor ein Medikament an den Markt kommt. Bei den Forschungen von PhytoMedical geht es um Volkskrankheiten wie Diabetes, sich immer stärker ausbreitende Krankheiten wie Alzheimer, aber auch die zwar nicht so bekannte, dafür aber dennoch stark verbreitete Kachexie. Es geht um Milliardenmärkte, die stark wachsen und für die vor allem bisher keine effektiven Therapien vorliegen.


Ein Blick auf die Forschungen lohnt. Quelle der Wirkstoffe, die PhytoMedical in der Entwicklung hat, ist eine Substanz, die jeder in der Küche hat: Zimt. In neuesten Forschungen mit Zimt wurden von unabhängigen Wissenschaftlern sehr positive Auswirkungen der Wirkstoffe auf den Blutzuckerspiegel nachgewiesen. In Tests haben die Wissenschaftler von PhytoMedical zudem nachgewiesen, dass Substanzen im Zimt den Blutzuckerspiegel um bis zu 29 Prozent gesenkt haben. Hintergrund ist, dass die Substanzen Schlüsselenzyme aktivieren und so den Körper in die Lage versetzen, das vorhandene Insulin effektiver zu nutzen. Nicht zuletzt haben Studien zudem ergeben, dass die Insulinfunktion auch eine Rolle bei Alzheimer zu spielen scheint.


Doch das ist nicht alles, im Gegenteil. Studien haben weiter gezeigt, dass sich Wirkstoffe, an denen PhytoMedical forscht, positiven Einfluss auf Cholesterinspiegel, Körperfett und Muskelmasse haben. Damit sind auch Kachexie-Patienten eine Zielgruppe für die Wirkstoffe von PhytoMedical. Unter Kachexie wird eine starke körperliche Auszehrung verstanden, die oftmals einher geht mit schwersten Krankheiten wie Krebs und eine der häufigsten eigentlichen Todesursachen bei solchen Erkrankungen ist. Kann man der Auszehrung wirksames entgegen halten, steigen die Überlebenschancen des Patienten erheblich.


Insgesamt ergeben sich immense Potenziale auf jedem einzelnen der Märkte, auf die sich PhytoMedical spezialisiert hat. Zudem ist das geringe Risikopotenzial der Wirkstoffe des Unternehmens, bei denen bisher keine Nebenwirkungen beobachtet wurden, extrem interessant. Die Herausforderung ist nun, die bioaktiven Wirkstoffe synthetisieren zu können, ohne dass möglicherweise toxisch wirkende Stoffe dabei sind. Gelingt dem Unternehmen dies, ist die Basis für eine lange anhaltende Hausse gelegt.


PhytoMedical hat daher das Zeug, zu einem der Highflyer der Branche zu werden. Das Unternehmen überzeugt vor allem mit den hinter ihr stehenden Wissenschaftlern und Managern. Kooperationen mit der Iowa State Universität und dem Forschungsdienst des US-Landwirtschaftsministeriums USDA geben dem Unternehmen die Möglichkeit, zu extrem kostengünstigen Konditionen an kommenden Blockbuster-Medikamenten zu forschen. Für weitere Kursgewinne ist damit eine sehr gute Basis gelegt. Zumal Gerüchten zufolge bei PhytoMedical in Kürze mit sehr positiven Entwicklungen in der Forschung zu rechnen ist.


PhytoMedical Technologies
Frankfurt: WKN A0B79T
New York: PYTO


-------------------------------------------------------------------------------------------------------------------------------

Wenn Sie unsere Informationen nicht mehr wünschen, dann klicken Sie bitte mit dem Betreff UNSUBSCRIBE auf den nachfolgenden Link: [e-mail]
Sie werden dann automatisch aus unserer Versandliste ausgetragen.

-------------------------------------------------------------------------------------------------------------------------------

[neilsn]

Antwort auf Beitrag Nr.: 21.155.016 von bonjabi am 11.04.06 09:29:06

habe ich auch gerade bekommen .. sieht gut aus..

kurs schön niedrig, habe mir eben auch mal ein paar stücke ins depot gelegt .. die marke von 1,40 € sollte in kürze wieder erreicht werden

schaun ma mal!!

[bonjabi]

Antwort auf Beitrag Nr.: 21.155.174 von neilsn am 11.04.06 09:39:04

ja liest sich echt super hab eine kleine pos. geholt bin mal gespannt auf die gerüchte die im umlauf sind

[GSTeam]

Mal schauen, ob und wann der Ticker hier mit dieser Meldung gespeist wird.
Dann könnte es nochmal einen Schub geben.

gsteam

[neilsn]

Antwort auf Beitrag Nr.: 21.155.174 von neilsn am 11.04.06 09:39:04

bin damals nach der erstempfehlung von TI auch reingegangen und konnte mich über satte 80% in ein paar wochen freuen .. hoffe es geht diesmal genau so

[neilsn]

wie ich sehe war es keine falsche entscheidung einzusteigen

ET6
Last 1,07
Change +0,09
High 1,07
Low 0,95
Open 0,95
Bid 1,02
Ask 1,07
Vol 104810
OI
Contr
Change% +9,18%
ChgLast 0,01
BidSup T
AskSup T
MPh

[bonjabi]

Antwort auf Beitrag Nr.: 21.155.529 von neilsn am 11.04.06 10:03:15

ja sieht doch schon sehr gut aus wenn dann noch eine news kommt

[schreigl]

der heutige tag gefällt mir ausgesprochen gut

[schreigl]

Kursdaten 11.04.2006 Frankfurt
Realtime:
11:24:51 1,07 +9,18%
+0,09

[schreigl]

volumen schon bei 146k
super kursentwicklung und keiner da

was soll´s freu ich mich halt alleine

[schreigl]

falls doch jemand da ist.....



Phyto Medical:
Immenses Blockbuster-Potenzial
An der Börse können Anleger viele Fehler machen, große wie kleine. Ein riesengroßer Fehler wäre es, Zukunftsbranchen bzw. deren aussichtsreiche Vertreter im Depot zu ignorieren. PhytoMedical Technologies (WKN: A0B79T) ist ein solcher Vertreter in der Biotechbranche.

Und nach fast einhelliger Meinung der Experten ist die Biotechnologie eine boomende Branche. Sie ist in der Lage, das dicke Loch an Neuentwicklungen zu füllen, das bei den großen Pharmaunternehmen nach vielen Forschungsflopps entstanden ist. Pharmaunternehmen zahlen viel Geld an oftmals hochspezialisierte Biotechunternehmen, die mit bahnbrechenden Entdeckungen aufwarten können. Viele Biotechriesen sind so entstanden, die heute in den bedeutenden Indizes der US-Börsen notieren.

Und die Zukunft, soviel ist sicher, wird weitere Stars hervorbringen. Dies auch vor dem Hintergrund, dass viele potenzielle Medikamentenwirkstoffe noch gar nicht entdeckt sind. Allein im weltweiten Reich der Pflanzen sind unter rund 250.000 Pflanzenarten gerade einmal 15 Prozent auf biologisch wirksame Stoffe untersucht. Dennoch hat das gereicht, um absolute Bestseller wie Aspirin zu entdecken, das seinen Ursprung in einer Baumrinde hat.

In einem solchen Raster bewegt sich PhytoMedical Technologies. Das amerikanische Unternehmen ist aber nicht nur aufgrund der Forschungsprojekte interessant, sondern auch aufgrund der Köpfe hinter dem Unternehmen. Das wichtigste Kapital von forschenden Unternehmen ist das Know-How des Managements und des wissenschaftlichen Teams. Und da hat PhytoMedical bisher absolut überzeugt. CEO Greg Wujek, früherer Senior Manager bei Forest Laboratories, war eine der treibenden Kräfte bei Andrx Laboratories, die in einem 1,9 Milliarden Dollar schweren Deal von Watson Pharmaceuticals aufgekauft wurden. Unter den Wissenschaftlern, mit denen PhytoMedical zusammen arbeitet, sind führende Experten, vielfach ausgezeichnet und deren Arbeiten bereits Gegenstand von zahllosen Veröffentlichungen in renommierten Fach- und Publikumsmagazinen war. Vor allem zu nennen ist hier Dr. George Kraus.

Die Projekte, an denen PhytoMedical forscht, haben allesamt das Potenzial, zu hoch interessanten Blockbustern zu werden. Auch wenn die Entwicklungsprozesse noch einige Zeit in Anspruch nehmen werden, ist dies für Anleger kein Grund, die Hände in den Schoß zu legen und zu warten. Im Gegenteil: Typisch für Biotechunternehmen ist, dass die Kursentwicklung der Aktien sich sehr stark an den Forschungsergebnissen orientiert. Werden Fortschritte erzielt oder kann ein Unternehmen Forschungspartner an Bord holen, wächst der Wert des Forschungsprojektes – die Aktien springen dann nicht selten stark nach oben. So lassen sich mit Biotechaktien starke Kursgewinne erzielen, lange bevor ein Medikament an den Markt kommt. Bei den Forschungen von PhytoMedical geht es um Volkskrankheiten wie Diabetes, sich immer stärker ausbreitende Krankheiten wie Alzheimer, aber auch die zwar nicht so bekannte, dafür aber dennoch stark verbreitete Kachexie. Es geht um Milliardenmärkte, die stark wachsen und für die vor allem bisher keine effektiven Therapien vorliegen.

Ein Blick auf die Forschungen lohnt. Quelle der Wirkstoffe, die PhytoMedical in der Entwicklung hat, ist eine Substanz, die jeder in der Küche hat: Zimt. In neuesten Forschungen mit Zimt wurden von unabhängigen Wissenschaftlern sehr positive Auswirkungen der Wirkstoffe auf den Blutzuckerspiegel nachgewiesen. In Tests haben die Wissenschaftler von PhytoMedical zudem nachgewiesen, dass Substanzen im Zimt den Blutzuckerspiegel um bis zu 29 Prozent gesenkt haben. Hintergrund ist, dass die Substanzen Schlüsselenzyme aktivieren und so den Körper in die Lage versetzen, das vorhandene Insulin effektiver zu nutzen. Nicht zuletzt haben Studien zudem ergeben, dass die Insulinfunktion auch eine Rolle bei Alzheimer zu spielen scheint.

Doch das ist nicht alles, im Gegenteil. Studien haben weiter gezeigt, dass sich Wirkstoffe, an denen PhytoMedical forscht, positiven Einfluss auf Cholesterinspiegel, Körperfett und Muskelmasse haben. Damit sind auch Kachexie-Patienten eine Zielgruppe für die Wirkstoffe von PhytoMedical. Unter Kachexie wird eine starke körperliche Auszehrung verstanden, die oftmals einher geht mit schwersten Krankheiten wie Krebs und eine der häufigsten eigentlichen Todesursachen bei solchen Erkrankungen ist. Kann man der Auszehrung wirksames entgegen halten, steigen die Überlebenschancen des Patienten erheblich.

Insgesamt ergeben sich immense Potenziale auf jedem einzelnen der Märkte, auf die sich PhytoMedical spezialisiert hat. Zudem ist das geringe Risikopotenzial der Wirkstoffe des Unternehmens, bei denen bisher keine Nebenwirkungen beobachtet wurden, extrem interessant. Die Herausforderung ist nun, die bioaktiven Wirkstoffe synthetisieren zu können, ohne dass möglicherweise toxisch wirkende Stoffe dabei sind. Gelingt dem Unternehmen dies, ist die Basis für eine lange anhaltende Hausse gelegt.

PhytoMedical hat daher das Zeug, zu einem der Highflyer der Branche zu werden. Das Unternehmen überzeugt vor allem mit den hinter ihr stehenden Wissenschaftlern und Managern. Kooperationen mit der Iowa State Universität und dem Forschungsdienst des US-Landwirtschaftsministeriums USDA geben dem Unternehmen die Möglichkeit, zu extrem kostengünstigen Konditionen an kommenden Blockbuster-Medikamenten zu forschen. Für weitere Kursgewinne ist damit eine sehr gute Basis gelegt. Zumal Gerüchten zufolge bei PhytoMedical in Kürze mit sehr positiven Entwicklungen in der Forschung zu rechnen ist.

PhytoMedical Technologies
Frankfurt: WKN A0B79T
New York: PYTO

Lesen Sie den kompletten Bericht zu PhytoMedical Technologies in der Ausgabe vom 06.12.2005. Melden Sie sich einfach unter http://www.tradinginsider.com gratis an. Oder tragen Sie sich unten mit Ihrer E-Mail Adresse ein und Sie gelangen kostenlos zur aktuellen PDF-Ausgabe.

[LastDrow]

PhytoMedical's Ongoing Diabetes Research Validated By New Study
Tuesday April 18, 9:15 am ET


PRINCETON, N.J.--(BUSINESS WIRE)--April 18, 2006--New study provides further evidence of the beneficial effects and biochemical actions of certain compounds in cinnamon that improve insulin function and lower risk factors for diabetes and cardiovascular disease.
ADVERTISEMENT


PhytoMedical Technologies, Inc. (OTCBB: PYTO - News; FWB: ET6) today announced a new study presented at Experimental Biology 2006 provided further new evidence of the beneficial effects and biochemical actions of certain compounds in cinnamon that improve insulin function, lower blood sugar levels and triglycerides (fatty acids in blood), and also act as anti-inflammatory agents, which may be useful in preventing or mitigating arthritis, allergies as well as other inflammatory diseases such as cardiovascular diseases.

This new study, presented by PhytoMedical collaborating scientist, Dr. Heping Cao, of the Beltsville Human Nutrition Research Center, United States Department of Agriculture, involved the investigation of the biochemical basis for the insulin-like effects of certain bioactive compounds in cinnamon. Results showed that these compounds, like insulin, increase the amount of three critically important proteins involved in the body's insulin signaling, glucose transport, and inflammatory responses.

"The study provides new biochemical evidence for the beneficial effects of cinnamon in potentiating insulin action and suggests anti-inflammatory properties for the antioxidants in cinnamon," states Dr. Cao. Other researchers involved in the study are Drs. Richard A. Anderson and Marilyn M. Polansky, of the Beltsville Human Nutrition Research Center, and Dr. Perry J. Blackshear of the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Through a collaborative research and development agreement, PhytoMedical is in the process of synthesizing the bio-active components found in cinnamon bark that increase insulin sensitivity by activating key enzymes that stimulate insulin receptors, while inhibiting the enzymes that deactivate them. A widely followed study published in Diabetes Care showed that as little as one gram a day of cinnamon in capsule form -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent.

Because cinnamon is not water soluble and contains certain harmful substances, ingesting large amounts of cinnamon over long periods may be toxic. In response, PhytoMedical is working to produce a safe, pharmacologically approved, synthetic compound that could be easily taken as a pill, or added to soft drinks or other liquids, with the end result being lower blood sugar levels through more efficient use of insulin.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB: PYTO - News; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical's first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in studies of growing animals.

For obese or overweight individuals, BDC-03's potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body's inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year -- nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit:

http://www.PhytoMedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit:

http://www.PhytoMedical.com/IR/PressReleases/20060418-1.html

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Contact:
PhytoMedical Technologies, Inc.
Ms. Karley L. Smith, 800-611-3388
or
www.PhytoMedical.com

--------------------------------------------------------------------------------
Source: PhytoMedical Technologies, Inc.

[LastDrow]

Antwort auf Beitrag Nr.: 21.260.740 von LastDrow am 20.04.06 19:43:39

Das ist doch wohl eine TopMeldung, aber der Kurs fällt seit die Meldung raus ist, oder hab ich da was falsch verstanden ??

[IcecreammanXL]

Hallo Zusammen!

Ist hier noch irgend jemand in Pyto investiert?
Oder warum gibt der Kurs seit ein paar Wochen so nach?

Weiß jemand etwas mehr?

Gruß.

[KA_beginner]

Ja bin noch investiert aber warum es in der letzten Woche so abwärts ging habe ich keine Ahnung. Bin immer noch der meinung das in der Aktie viel Potential liegt. Aber so ist das eben mit kleinen Biotechfirmen. Die geht auch mal ohne News bzw. vielleicht auch weil keine neuen News kommen mal um 20-30% nach unten. Das kann sich aber auch schnell wieder drehen man muss bei solchen werten einfach geduld mitbringen. War davor in Hana Biosciences investiert da war es das gleich kaum war ich investiert ging der wert 20% nach unten, schlussendlich habe ich dann knapp 80% gewinn gehabt. Leider zu früh verkauft sonst hätte ich jetzt etwa 250%.
Naja das ist eben Börse! Wenn man immer nur den richtigen Kauf bzw. Verkaufszeitpunkt treffen würde.

Gruß
KA_Beginner

[Elsner]

Antwort auf Beitrag Nr.: 21.488.042 von KA_beginner am 09.05.06 13:17:24

Bin nach wie vor auch noch dabei. Auch wenn diese Aktie langsam aber sicher meine Nerven strapaziert. Ist hier ja wie Wellenreiten.

Jedesmal, wenn man hofft, dass jetzt der Anstieg richtig beginnt und deshalb weiter hält, fällt der Kurs wieder in sich zusammen. Die Angst, dass der nachhaltige Anstieg genau mit dem Aussteigen beginnt, hat mich bisher vom Verkaufen abgehalten. Mal sehen, wie lange ich mir das noch zumute.

[LastDrow]

Seit gestern gehts ja wieder aufwärts.
Wurde PYTO evtl. irgendwo gepusht ??
Wenn nicht wäre das umso besser

Wieder über 1 $ !
Bei dieser Aktie muß man wirklich cool bleiben....Mit engen Stopps ist einem da nicht geholfen !

Gruß
LastDrow

[breeze77]

PhytoMedical and Iowa State University Research Foundation Announce a License Agreement for Novel Synthesized Compounds
PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6), through its wholly owned subsidiary, today announced that it has entered into an exclusive license agreement with Iowa State University Research Foundation Inc. (ISURF) to develop, market and distribute novel synthesized compounds derived from type A-1 polyphenols, which have been linked to insulin sensitivity by lead researcher, Dr. Richard Anderson of the USDA's Agricultural Research Service.

Under terms of the agreement, PhytoMedical paid an upfront license fee to ISURF, and agreed to pay future undisclosed milestone payments. In addition, ISURF will receive royalty payments based on sales. PhytoMedical will administrate the development, regulatory approval and commercialization of the compounds. Additionally, PhytoMedical will pursue future collaborative arrangements.

The innovative synthesized type A-1 polyphenols will be developed by PhytoMedical as a new class of compounds for type 2 diabetes. A published study confirmed that these compounds are able to improve insulin sensitivity and reduce blood sugar levels by up to 29%. An additional range of applications for these compounds includes Alzheimer's, cancer, and cardiovascular disease.

According to a recent study published in Diabetes Care, over 73 million adults now suffer from diabetes or have higher than normal blood sugar levels. At a cost of $132 billion, the overall prevalence of diabetes is now 9.3% of the US population, including 6.5% diagnosed and 2.8% undiagnosed. Diabetes is the sixth leading cause of death, and the leading cause of lower limb amputations. In all cases, insulin function is critical to the treatment of diabetic patients.

In addition to improving insulin function and lowering blood sugar levels, recent research shows that these particular polyphenols also act as antioxidants, guarding the body from the damaging effects of free radicals. Free radicals often contain oxygen and are highly reactive chemicals that may destroy healthy cells and play an active role in many illnesses, including cardiovascular disease and cancer.

Greg Wujek, President and CEO commented: "We are very pleased having entered into this agreement with Iowa State University. Dr. George Kraus, who led the synthesis project, is a noted expert in the area of compound synthesis. The development of the synthesized type A-1 polyphenols is leading the way to a new class of compounds. We are just scratching the surface as the potential application of these compounds is enormous in diabetes, cancer, Alzheimer's and cardiovascular disease."

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO) (Frankfurt Stock Exchange:ET6), together with its wholly owned subsidiaries, is an early-stage research-based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant-derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical's first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals.

For obese or overweight individuals, BDC-03's potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body's inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year -- nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit http://www.phytomedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit:

http://www.PhytoMedical.com/IR/PressReleases/20060613-1.html

[IcecreammanXL]

Hi Zusammen

News News!!

PHYTOMEDICAL TEHNOLOGIES Quick Quote: PYTO 0.54 (-0.01)

PhytoMedical Announces Key Developmental Partner For New Cachexia Compound, Which Has Active Elements That Increase Lean Muscle Mass and Reduce Body Fat
7/10/2006

Ricerca Biosciences Brings over 18 Years and 200 Pharmaceutical
Companies Worth of Experience

PRINCETON, N.J., Jul 10, 2006 (BUSINESS WIRE) --
PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) (WKN:A0B79T) announced today that it has entered into a development agreement with Ricerca BioSciences, a world class pharmaceutical development lab. "This is a historic milestone in the life of PhytoMedical," commented Mr. Greg Wujek, President and CEO of PhytoMedical. "Partnering with a sophisticated and respected lab such as Ricerca provides us with a complete range of developmental capabilities, allowing us to quickly transition from pre-clinical to clinical."

Effective immediately, Ricerca will begin developmental work on PhytoMedical's BDC-03 compound for cachexia, a devastating muscle wasting condition that afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

BDC-03 has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals. Ricerca's responsibilities will eventually expand to include PhytoMedical's other compounds.

About Ricerca

Ricerca Biosciences, LLC, a drug development company, offers an extensive drug development system that improves the odds of converting drug discovery leads to optimal drug candidates, rapidly taking them over the preclinical hurdles to IND filing, and continues with support of clinical trials. Ricerca is an integrated solutions provider.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) (WKN: A0B79T), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical's first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals.

For obese or overweight individuals, BDC-03's potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body's inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year -- nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon -- one-fourth of a teaspoon twice a day -- can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or "bad") cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL ("good") cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com

Bitte um eure Meinung zu den News und zu Phyto.

[CRJ200]

Naja, anscheinend wurde das nicht gerade positiv aufgenommen, denn die Aktie ist heute gleich um über 6% ins Minus gerutscht!? Hat jemand eine Ahnung, was da los ist/war?
Die News sind ja eigentlich nicht so schlecht, oder?

[delphin71]

Antwort auf Beitrag Nr.: 22.537.269 von CRJ200 am 12.07.06 09:41:35

Was ist wirklich los?Wann kommen entscheidende Nachrichten?

LG
Delphin

[emrahs]

hallo - bin neu hier - habe mich aber mit dieser aktie eingedeckt - nur bin leider zum höchst kurs eingestiegen - jetzt ist die aktie fast am boden - jetzt weiß ich nicht mehr so genau, ob dies alles war oder kommt da noch was positives - damit ich meine hohen verluste wieder neutralisieren kann - ich denke ich brauch jetzt dringend info und vielleicht seelisch helfende unterstützung.

danke schon mal im voraus

[LastDrow]

Antwort auf Beitrag Nr.: 23.145.978 von emrahs am 28.07.06 09:41:25

Hi emrahs !
PYTO ist ein OTC Wert, also ein ganz heißes Zockerding !
Ich bin auch im Minus, aber hoffe für Dich, das Du nur mit einer relativ kleinen Summe investiert bist.

Ohne Schönfärberei: Selbst bei 0,01 € gehts noch tiefer....

Aber keine Bange, bin ja auch noch investiert, weil ich an das Geschäftsfeld glaube. Wenn sich das Börsenumfeld bessert werden auch "Heiße" Werte wie PYTO wieder gespielt.

[emrahs]

Antwort auf Beitrag Nr.: 23.158.210 von LastDrow am 28.07.06 21:29:52

hmmm...4000 stück für 1,30 habe ich mir damals zugelegt und jetzt das dilemmer - bin ziemlich down deswegen

trotzalledem - danke für deine moralische unterstützung


gruß

[emrahs]

Antwort auf Beitrag Nr.: 23.158.210 von LastDrow am 28.07.06 21:29:52

...hallo

warum ist es hier so still im thread
hier regt sich ja noch nicht mal ein blatt

[Meganonn]

Antwort auf Beitrag Nr.: 23.461.852 von emrahs am 15.08.06 23:18:33

Habe mir heute in Fr./M. wieder einen ordentlichen Batzen PYTO ins Depot gelegt ... zu 0,34 € !

Der letzte Trade vom 14.02. - 29.03.06 war ja schon recht erfolgreich. Auf dem jetzigen Kursniveau der PHYTOMEDICAL TECHNOLOGIES INC. erscheint mir das Chancen-/Risikoprofil wieder sehr vielversprechend (gerade wg. der Abstinenz von Pusherbörsenbriefen).

Bis zum Jahresende rechne ich wenigstens mit einer Kursverdoppelung dieses vom insgesamt allgemein negativen Biotechsentiment "ausgebombten" Unternehmens.

Grüsse
M.

[delphin71]

Antwort auf Beitrag Nr.: 23.484.161 von Meganonn am 17.08.06 16:37:42

MELDUNG VOM 6.9.2006

PhytoMedical Announces Addition of Proven Industry Executive.

Drug Development and Commercialization Expert, James F. Lynch, PhD, MBA, joins Scientific Advisory Board.

Princeton, NJ – September 6, 2006 - PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced the addition of James F. Lynch, PhD, MBA, President of Strategic Access, Inc., to its Scientific Advisory Board.

Dr. Lynch brings over two decades of pharmaceutical industry experience to PhytoMedical, ranging from scientific research and drug development, to holding executive and management/consulting positions with successful startups and Fortune 500 companies including Pfizer, Inc. and Sandoz Pharmaceutical Corporation (now, Novartis Pharmaceutical Corporation).

Prior to joining PhytoMedical, Dr. Lynch served as Vice President, Global Business Development at Savient Pharmaceuticals, a specialty pharmaceutical company. Previously, he was a founding member of Reliant Pharmaceuticals, LLC, a start-up company where he served as Executive Director of Business Development and Vice President of Commercial Operations.

As a Managing Consultant with PA Consulting Group, a UK-based global technology consulting firm, Dr. Lynch directed global projects for major pharma clients including the world’s largest pharmaceutical company, Pfizer, Inc., focusing on strategic portfolio planning, drug development harmonization, capacity/capabilities assessment and outsourcing.

Dr. Lynch spent nine years at Sandoz/Novartis where he held numerous managerial positions in various functional areas, including New Product Management and Licensing, Drug Development and Project Lead for Cardiovascular and Diabetes Drug Development.

Commenting on today’s announcement, Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc. stated, “In addition to his extensive industry-wide experience, Dr. Lynch’s unique blend of scientific know-how and commercial drug development expertise in diabetes and cardiovascular disease are especially helpful to us.

“We look forward to working with Dr. Lynch in these areas, and furthering the development of our compounds.

“I welcome Jim to our team and am eager to leverage his many years of experience as we move these promising compounds along the commercialization track, and towards filing IND applications with the FDA,” Mr. Wujek explained.

Dr. Lynch is an active member of Licensing Executives Society, Venture Association of New Jersey, Biotechnology Council of New Jersey and the Crohn’s and Colitis Foundation of America.

Dr. James F. Lynch earned his Bachelor Of Science (BS) degree in Chemistry at Siena College, subsequently completing his Masters (MS) and Doctoral (PhD) degrees in Inorganic Chemistry at Seton Hall University, and a Masters in Business Administration (MBA) at Columbia University.

About PhytoMedical Technologies, Inc.

PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds. Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.

BDC-03 Successful in Increasing Lean Muscle Mass and Reducing Body Fat Percentage

Named BDC-03, PhytoMedical’s first plant derived compound has pharmacologically active elements that have been successful in reducing body fat percentage, increasing lean muscle mass and lowering cholesterol in a study of growing animals.

For obese or overweight individuals, BDC-03’s potential capacity to decrease the deposition of fat and lower cholesterol would be a vitally important therapeutic outcome. However, its prospective ability to induce overall weight gain in the form of lean muscle mass may well be the difference between life and death for individuals suffering from cachexia.

Cachexia, which is characterized by dramatic weight loss, not only of fatty tissue, but also muscle tissue and bone, is among the most devastating and life-threatening aspects of AIDS and cancer. Once the body loses 30% of its lean muscle mass, major organs are affected, resulting in death.

Sadly, cachexia afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients. In fact, half of all cancer related deaths are a result of cachexia, not the cancer itself.

Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20

Diabetes, which results from the body’s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year – nearly one out of every ten health care dollars spent in the United States.

While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including, glucose, insulin, cholesterol, triglycerides and related variables.

A study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon – one-fourth of a teaspoon twice a day – can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or “bad”) cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL (“good”) cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.

Through a Cooperative Research and Development Agreement, PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects in cell cultures systems, animals and ultimately humans.

At present, the Company does not currently have commercial products intended to diagnose, treat, cure or prevent any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit www.PhytoMedical.com

To receive future press releases via email, please visit http://www.phytomedical.com/Alerts-Index.asp

To view the full HTML text of this release, please visit:
http://www.PhytoMedical.com/IR/PressReleases/20060906-1.html

[emrahs]

Antwort auf Beitrag Nr.: 23.855.318 von delphin71 am 10.09.06 10:30:34

...mein english ist nicht so gut - kannst du mir dies vielleicht in der verkürzten und in deutscher sprache noch einmal wiedergeben - danke nochmals im voraus


gruß

emrahs

[Daisy500]

Antwort auf Beitrag Nr.: 23.856.002 von emrahs am 10.09.06 11:19:13

Hallo emrahs,
hier die Meldung vom 6.9., ungekürzt aber einigermaßen verständlich

Übersetzt wurde mit http://babelfish.altavista.com/tr


Princeton, NJ - September 6, 2006 -
PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) verkündete heute die Hinzufügung von James F. Lynch, PhD, MBA, Präsident von Strategic Access, Inc., zu seiner wissenschaftlichen Beratungsstelle.

Dr. Lynch holt PhytoMedical über zwei Dekaden der pharmazeutischen Industrieerfahrung und reicht von der wissenschaftlichen Forschung und von der Drogeentwicklung, bis zu dem Halten des Hauptleiters und der management/consulting Positionen mit erfolgreichen Starts und Vermögen 500 Firmen einschließlich Pfizer, Inc. und Sandoz Pharmaceutical Corporation (jetzt, Novartis Pharmaceutical Corporation).

Vor dem Verbinden von PhytoMedical, diente Dr. Lynch als Vizepräsident, globale geschäftliche Entwicklung an den Savient pharmazeutischen Produkten, eine Spezialgebiet pharmazeutische Firma. Vorher war er ein Gründung Mitglied der vertrauensvollen pharmazeutischer Produkte, LLC, eine Start-upfirma, wo er als Executivdirektor der geschäftliche Entwicklung und Vizepräsident der kommerziellen Betriebe diente.

Als handhabender Berater mit PA beratener Gruppe, verwies ein Großbritannien-gegründetes Beratungsunternehmen der globalen Technologie, Dr. Lynch globale Projekte für Hauptpharma Klienten einschließlich die größte pharmazeutische Firma der Welt, Pfizer, Inc. und konzentrierte auf strategische Bestimmung des Anlageziels, Drogeentwicklung Harmonisierung, capacity/capabilities Einschätzung und Outsourcing.

Dr. Lynch verbrachte neun Jahre Sandoz/Novartis, wo er zahlreiche Verwaltungspositionen in den verschiedenen Funktionsbereichen, einschließlich neues Produkt-Management und das Genehmigen hielt, Droge-Entwicklung und Projekt-an der Leitung für Herzgefäß- und Diabetes-Droge-Entwicklung.

Kommentieren heutige Ansage, Herr Greg Wujek, Präsident und CEO von PhytoMedical Technologies, Inc. angegeben, "zusätzlich seiner umfangreichen industrieweiten Erfahrung, einzigartigen Mischung des Dr. Lynchs des wissenschaftlichen Know-hows und kommerziellen zu Drogeentwicklung Sachkenntnis im Diabetes und in der Herzgefäß- Krankheit besonders behilflich uns.

"wir freuen, mit Dr. Lynch in diesen Bereichen zu arbeiten und die Förderung der Entwicklung unserer Mittel.

"ich begrüße Jim zu unserer Mannschaft und zu morgens, die eifrig sind, seins langjährige Erfahrung, während wir diese versprechenden Mittel entlang der Kommerzialisierungschiene verschieben, und in Richtung zu den Archivierung IND Anwendungen mit der FDA wirksam einzusetzen," Herr erklärtes Wujek.

Dr. Lynch ist ein aktives Mitglied der genehmigenden Hauptleiter-Gesellschaft, Wagnis-Verbindung von Neu-Jersey, Biotechnologie-Rat von Neu-Jersey und von Crohns und Colitis Grundlage von Amerika.

Dr. James F. Lynch erwarb seinen Bakkalaureus der Wissenschaften (BS) Grad in der Chemie an der Siena Hochschule und nachher führte seine Meister (MS) und Doktor (PhD) Grad in der anorganischen Chemie Seton Hall an der Universität durch, und Meister in der Geschäft Leitung (MBA) an der Kolumbien Universität.


Über PhytoMedical Technologien Inc.. PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Börse: ET6), zusammen mit seinen insgesamt besessenen Tochtergesellschaften, ist eine frühes Stadium Forschung gegründete biopharmaceutical Firma, die auf die Kennzeichnung, den Erwerb, die Entwicklung und die etwaige Kommerzialisierung der erfinderischer Betrieb abgeleiteten pharmazeutischen und nutraceutical Mittel gerichtet wird, die Cachexia, Korpulenz und Diabetes zielen.

Bleiben geschätzte 300 neue Drogen des weltweiten Wertes, Wert über $150 Milliarde, weiterhin, unter den 250.000 Sorten der höheren Betriebe entdeckt zu werden, die auf Masse gefunden werden, von der weniger als 15% für bioactive Mittel nachgeforscht worden sind. Momentan kommen Zwanzig der besten verkaufenden Drogen von den natürlichen Quellen und 25% aller Verordnungdrogen enthalten die aktiven Mittel, die ursprünglich von abgeleitet werden oder nach den Mitteln patterned, die von den Betrieben abgeleitet werden.

BDC-03 erfolgreich, wenn magere Muskel-Masse erhöht wird und Körperfett-Prozentsatz verringert wird Genannter BDC-03, PhytoMedicals erster Betrieb abgeleitetes Mittel hat pharmakologisch aktive Elemente, die erfolgreich gewesen sind, wenn sie Körperfettprozentsatz verringerten, zunehmende magere Muskelmasse und Cholesterin in einer Studie der wachsenden Tiere senkten.

Für die beleibten oder überladenen Einzelpersonen BDC-03's würde die mögliche Kapazität, die Absetzung des fetten und untereren Cholesterins zu verringern ein lebenswichtig wichtiges therapeutisches Resultat sein. Jedoch kann seine zukünftige Fähigkeit, gesamten Gewichtgewinn in Form von magerer Muskelmasse zu verursachen hervorquellen ist der Unterschied zwischen dem Leben und Tod für die Einzelpersonen, die unter Cachexia leiden.

Cachexia, der durch drastischen Gewichtverlust, nicht nur des fetthaltigen Gewebes, aber auch Muskelgewebe und Knochen gekennzeichnet wird, gehört zu den verheerendsten und lebensbedrohendsten Aspekten von AIDS und von Krebs. Sobald der Körper 30% seiner mageren Muskelmasse verliert, werden Hauptorgane beeinflußt, und das resultiert im Tod.

Traurig betrübt Cachexia 25% aller AIDS-Patienten und aufwärts des 90% aller vorgerückten Krebspatienten. Tatsächlich sind Hälfte aller Krebs bezogenen Todesfälle ein Resultat des Cachexia, nicht der Krebs selbst.

Polyphenolmittel erhöhen Zuckermetabolismus durch einen Faktor von 20

Diabetes, der aus der Unfähigkeit des Körpers, genügend Insulin zu produzieren oder es leistungsfähig zu benutzen resultiert, beeinflußt 18.2 Million Leute in den Vereinigten Staaten oder 6.3% der Bevölkerung (amerikanische Diabetes-Verbindung). Die Mitten zur Krankheit-Steuerung und der Verhinderung erwartet diese Zahl, um sich bis über 30 Million um 2030 zu erhöhen. Wie die führende Ursache Ende-Stadium der Nierenkrankheit, der Blindheit und der untereren GliedAmputierungen, Diabetes jetzt das Gesundheitspflegesystem über $132 Milliarde jedes Jahr - fast eins aus jeden 10 Gesundheitspflegedollar heraus kostet, die in den Vereinigten Staaten ausgegeben werden.

Während die Ursachen von Diabetes nicht völlig klar sind, wird es gewußt, daß Diät eine Schlüsselrolle in der Verhinderung und in der Heilung von Diabetes spielt. Tatsächlich haben Forschung Studien, daß wäßrige Extrakte des am allgemeinsten verbrauchten Gewürzs, Zimt, die Tätigkeit des Insulins verbessert und hilft, die Gefahr Faktoren zu steuern, die mit Diabetes einschließlich verbunden sind, Glukose, Insulin, Cholesterin, Triglyzeride und bezogene Variablen gezeigt.

Eine Studie veröffentlicht in der Diabetes-Obacht, ein Journal der amerikanischen Diabetes-Verbindung, gezeigt, daß so wenig wie ein Gramm ein Tag des Zimts - ein viertel eines Teelöffels zweimal täglich - Blutzucker durch einen Durchschnitt von 18 bis 29 Prozent, Triglyzeride (Fettsäuren im Blut) durch 23 bis 30 Prozent, LDL (oder "Schlechtes") Cholesterin durch 7 bis 27 Prozent und Gesamtcholesterin durch 12 bis 26 Prozent senken kann. Änderungen HDL ("gut") im Cholesterin waren nicht bedeutend. Erstaunlich fand die Studie, daß die vorteilhaften Effekte des Zimts für mindestens dauerten, 20 Tage nachdem Leute stoppten, sie zu nehmen.

Durch eine kooperative Forschung und Entwicklung Vereinbarung arbeitet PhytoMedical in Richtung zum Synthetisieren der Wirkanteile, die im Zimt gefunden werden und zum Kennzeichnen ihrer vorteilhaften Gesundheit Effekte in den Zellkultursystemen, -tieren und schließlich -menschen. Zur Zeit läßt die Firma z.Z. Handelsprodukte beabsichtigen, um keine Krankheit zu bestimmen, zu behandeln, zu kurieren oder zu verhindern. ....


Gruß Daisy

[emrahs]

Antwort auf Beitrag Nr.: 23.915.935 von Daisy500 am 13.09.06 19:28:29

vielen dank für die eins zu eins übersetzung - habe einen kleinen einblick bekommen, aber der wert scheint sich durch diese teilweise positive meldung gar nicht richtig vom negativen unterem boden lösen zu wollen - er tendiert immer nur noch nach unten und das stimmt mich traurig


gruß

emrahs

[Meganonn]

Antwort auf Beitrag Nr.: 24.182.393 von emrahs am 25.09.06 11:21:15

... und das stimmt mich traurig

Vielleicht hebt sich Deine Stimmung nun wieder, da der PYTO-Kurs wieder kräftig anzieht.

Bin selbst vor einigen Wochen wieder zu 0,34 € eingestiegen, nachdem ich PYTO im zeitigen Frühjahr einmal recht erfolgreich getradet habe ...

[Meganonn]

Antwort auf Beitrag Nr.: 24.346.135 von Meganonn am 02.10.06 17:11:06

Nachtrag:

... entweder ist dort bei PhytoMedical was im Busche, oder es ist nur die Folge der heute wieder untermauerten Übernahmephantasie für (US-)Biotech-Aktien (aktuell: US-Pharmaunternehmen Gilead übernimmt Myogen für 2,5 Milliarden US-Dollar).

Grüsse
M.

[SVA]

Antwort auf Beitrag Nr.: 24.346.293 von Meganonn am 02.10.06 17:17:27

Heut könnts auch wieder mal recht werden!!!

[Meganonn]

Antwort auf Beitrag Nr.: 24.572.577 von SVA am 12.10.06 09:22:56

Die Handelsaktivitäten (vgl. Umsätze zum Kursverlauf) der letzten Tage in den USA deuten m.E. darauf hin, dass PYTO zunächst ein weiterer, diesmal sehr kräftiger Kursschub von wenigstens 20 - 30 %unmittelbar bevorsteht ... vielleicht wird im Anschluss gar der alte Höchstkurs bei ca. 1,70 USD "wiederbelebt", sollte dies von positivem Newsflow zu Entwicklungsfortschritten in der F+E Pipeline begleitet werden (man kooperiert ja auch mit nahmhaften US-Unis).




Noch ist´s freilich nur ein "Bauchgefühl" aus langjähriger Börsen-Erfahrung.

[Meganonn]

Antwort auf Beitrag Nr.: 24.572.971 von Meganonn am 12.10.06 09:42:05

gemeint war ...

... sehr kräftiger Kursschub von wenigstens 20 - 30 Cent unmittelbar bevorsteht ...

[emrahs]

das wird wohl dieses jahr nichts mehr

und nächstes jahr

langsam bekomme ich frust und verkaufe vielleicht noch dieses jahr

zukunft keine

[Meganonn]

Antwort auf Beitrag Nr.: 24.573.060 von Meganonn am 12.10.06 09:45:51

... sehr kräftiger Kursschub von wenigstens 20 - 30 Cent unmittelbar bevorsteht ...

So war es denn auch und ich habe mit meinen Verkäufen am 30.11. u. 01.12.06 einen ansehnlichen Tradinggewinn einfahren können ... war fast ein Verdoppler und bei 15 k PYTO-Bestand bin ich dann - wenngleich seinerzeit suboptimal noch etwas zu früh - der Versuchung erlegen (vgl. # 19 im Thread: PHytomedical,geht da was!?).

Wünsche allen Investierten viel Glück.

Grüsse
M.

[Meganonn]

Antwort auf Beitrag Nr.: 26.526.833 von Meganonn am 28.12.06 19:51:11

So ... habe mich gerade in Stuttgart wieder mit 11 k Pyto eingedeckt (dank Nasi-Krach).

Auf ein Neues.

Grüsse
M.

[Meganonn]

Antwort auf Beitrag Nr.: 26.696.238 von Meganonn am 05.01.07 17:38:58

Sieht fast so aus, als gäbe es in Kürze wieder eine Kaufwelle.

http://finance.yahoo.com/q?s=PYTO.OB

[Knocky]

::ma
::mad::
::ma
::mad::madd:mad::madd:

[Knocky]

:ma:mad:d:

[CRJ200]

Wer ist hier noch investiert?
Gibt es eigentlich irgendwelche News von Phytomedical bzw. warum geht es schon seit längerem nur mehr abwärts?

[Meganonn]

Antwort auf Beitrag Nr.: 27.827.677 von CRJ200 am 19.02.07 17:09:03

... meine Wenigkeit ist noch investiert (s.u.# 137) !

Wie es scheint, tut sich bei PYTO nun auch etwas ... möglicherweise besteht hier ein Zusammenhang mit folgender interessanter Meldung aus jüngster Vergangenheit: Expert in Pharmaceutical Sciences and New Drug Applications to FDA Joins PhytoMedical - Wednesday February 21, 9:15 am ET [url(Details hier anklicken)]http://biz.yahoo.com/bw/070221/20070221005360.html?.v=1[/url]

Jedenfalls lassen sich gerade heute in FFM unübliche und sehr ungewöhnliche Handelsaktivitäten in PYTO feststellen.

Times + Sales Frankfurt 13 Uhr
Zeit Kurs Umsatz
11:15:25 0,460 40.000
10:34:09 0,400 2.000
09:23:15 0,360 0

M.E. ist das was im Busche.

[SVA]

Antwort auf Beitrag Nr.: 28.000.976 von Meganonn am 27.02.07 13:12:27

Bin auch noch dabei und bleib es auch.Weiß aber auch nichts neues.40.000 zu Höchstkurs, da weiß jemand schon mehr!!!

sva